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L2PB1 CELLS ARE ESSENTIAL FOR THE INHIBITION OF 3D TUMOR 
SPHEROIDS BY SYNGENEIC PERITONEAL IMMUNE CELLS 
 
ALI H. BOOTWALA 
ABSTRACT 
Introduction: Programmed Death Ligand 2 positive B1 cells (L2pB1) cells have 
a unique immunoglobulin repertoire that is poly-reactive to self-antigens and 
have previously been shown to have an essential role in autoimmunity. The 
active accumulation of L2pB1 cells inside tumors grown in vivo led us to 
hypothesize that this subpopulation of B1a cells may play a role in the 
immunosurveillance of cancer. Here, we report our investigation of the role of 
L2pB1 cells in the antitumor response using a three dimensional (3D) murine 
melanoma and colon cancer models. Our results showed that the depletion of 
L2pB1 cells rendered the loss of tumor inhibition effects of the syngeneic 
peritoneal immune cells. 
Methods: Lymphocytes were collected from L2pB1 cell depleted and non-
depleted peritoneal cavity washout (PCW) from an inducible knockout mouse 
model. Then tumor spheroids were incubated with PCW cells. Spheroid cross-
sectional area (CSA) and volume were measured using a Celigo plate imager 
and Keyence fluorescence microscope. 
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Results: Tumor spheroid growth was significantly inhibited following incubation 
with syngeneic PCW but not with splenocytes. Depletion of L2pB1 significantly 
attenuated the tumor-inhibition effect and showed a negligible difference from the 
untreated control. This loss of tumor inhibition indicated that L2pB1 cells are 
essential for the tumor-inhibition effects of autologous peritoneal immune cells. 
Conclusions: These findings demonstrate the robust anti-tumor function of 
L2pB1 cells. In particular, peritoneal L2pB1 cells play an essential role in cancer 
inhibition. Future studies into the activation and antigen presentation pathways of 
L2pB1 cells could lead to novel immunotherapy of cancer. 
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INTRODUCTION 
In 2013 over 1.5 million invasive cancers were diagnosed and reported to 
cancer registries in the United States alone. The age-adjusted annual incidence 
rates for all cancers reported was 439 per 100,000 persons and increased with 
increasing age [1]. The research of novel cancer therapy has recently turned 
away from the production of chemical and pharmaceutical reagents to instead 
focus on immunotherapies designed to understand, activate, and recruit nature’s 
first antitumor agents, the immune cells.  
Cancer, also known as malignancy, can be a chronic disease and involves 
long-term immune engagement in recognizing and eliminating precancerous 
cells. In the lifetime of a multicellular organism, there is permanent exposure to 
spontaneously arising or induced mutant cells. However, while every individual 
multicellular organism exposes itself to many of these transformed cells, not 
every transformed cell poses the threat of malignancy [2]. When the prevalence 
of transformed cells is compared to the aforementioned relatively low invasive 
cancer incidence rates, the realization becomes that it is astounding that so few 
malignancies occur. 
The low rate of malignancy in the multicellular organism can be attributed 
mainly to early recognition and rapid elimination of newly transformed cells by 
immune mechanisms, which are essential for keeping an organism free of tumor 
cells. This early response mechanism is known as innate or natural immunity and 
has in the past been defined as nonspecific background immunity. The 
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importance of innate immunity in the defense against bacterial infections is well 
recorded as is the effect of T cells in the antitumor response. However, roles of B 
cells and B cell produced natural antibody in the antitumor response is still an 
under-explored area [2], [3]. 
B cell and antibody responses to tumor antigens have resulted in the 
discovery of distinct B cell populations that are differentiated by the surface 
marker and antigen presenting cell (APC) capacity and stem from independent 
progenitor cell lines [4]. L2pB1 cell is a newly discovered B cell population 
bridging the innate and adaptive immunity [5]. The presence of L2pB1 cells in 
mouse tumor suggested that it may play a role in the immunosurveillance of 
tumor (X. Zhong unpublished data) 
While in vivo studies in animal models remain the most accurate method 
for studying the mechanisms of immune cells in their natural state, 
advancements in cell culturing, fluorescence activated cell sorting (FACS), and 
other in vitro methodologies has given rise to high throughput assays that allow 
the study of tumor cells with various drug or immunologic therapies. However 
current standard methods for the study of immune cell invasion still rely primarily 
on two-dimensional Transwell or Boyden-chamber based assays [6]. These 
assays provide significant insight into the nature of immune responses and tumor 
invasion, but the two dimensional (2D) monolayers lack stroma and structural 
architecture that make up a majority of the tumor microenvironment. These 
limitations prompted the movement to use the three dimensional (3D) tumor 
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spheroid assays that better represent the inherent complexities and 
pathophysiology of the disease, in addition to the requirements of human tissue 
development and the regulatory properties of cell-cell signaling in the tissue 
microenvironment[7]. By utilizing a 3D tumor model, in vitro studies can be better 
predictors of in vivo tumor and immune cell activity. 
This study combines previous work on the L2pB1 cell and 2D in vitro 
assays with the culture of round and even edged 3D tumor spheroids of a murine 
melanoma cell line and colon cancer cell line to further assess the anti-tumor 
properties of L2pB1 cell, the immune cell under investigation. 
The role of IgM in the natural immune response to cancer 
Advances in human hybridoma technology have offered the opportunity to 
study the recognition and elimination of aberrant (transformed) cells by human 
monoclonal antibodies (mAbs). This hybridoma technique (Trioma technique) 
has been used to isolate thousands of tumor-reactive antibodies from cancer 
patients and healthy donors. In a study conducted by Brändlein et al. in 2003 
over 18,000 growing triomas were investigated by ELISA for antibody production, 
and of the human antibodies produced, all tumor-specific antibodies were of the 
immunoglobulin M (IgM) class. The IgM class of antibodies is the primary 
antibody component of the innate (natural) humoral immune response, and due 
to certain features of the IgM isotype, it has not been utilized and thoroughly 
investigated for use in immunotherapy. However, this line of inquiry is particularly 
important as there is still little data on the specific role of innate immunity in the 
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tumor defense of humans and recent research shows that these antibodies and 
the immune cells that create them are a crucial part of this disease prevention 
pathway [2].  
IgM antibodies are the main component of natural antibodies that are 
present in human serum before any external antigen stimulation. IgM is the most 
evolutionarily conserved isotype; present in all vertebrates and is the first isotype 
to be expressed during immune development [8]. These natural IgM antibodies 
are polyreactive to phylogenetically conserved structures including nucleic acids, 
heat shock proteins, carbohydrates, and phospholipids. The exact function of the 
polyreactive and autoreactive IgM antibodies has long been under debate [9]. 
The secreted IgM molecule is a pentamer joined by J chain peptide 
groups that can potentially bind to 10 antigenic determinants per molecule, the 
polyreactivity allows reaction with a broad spectrum of antigens simultaneously, 
and IgM is a potent complement activator [9], [10]. A single IgM pentamer has a 
thousand fold greater binding affinity to C1q (an early complement protein) than 
an IgG class antibody [11]. The IgM antibodies are also the first class of 
antibodies produced by activation from initial antigen (Ag) exposure [2]. Most Ags 
initiate a humoral immune response that is characterized by a rise in Ag-specific 
IgM followed by activation of further adaptive immune responses [10]. In fact, a 
review by Ochsenbein and Zinkernagel demonstrated a link specifically between 
natural IgM antibodies and the acquired (adaptive) immune response. They 
reported that natural IgM antibodies enhance the targeting of antigen particles to 
 5 
lymphoid organs through a pathway that is mostly independent of the 
complement system, meaning that it is possible that natural IgM is by itself able 
to link the humoral and acquired immune response to certain Ags [12].  
In both human cord blood of infants and Ag-free mice, spontaneously 
produced IgM has been detected and IgM secretion has been linked to long-
lived, self-renewing B1 cells (a subset of B cells to be further discussed later). 
Natural IgM is found in the absence of antigenic stimulation and is encoded by 
germline V gene segments. The precursor B cells in the natural IgM secreting 
lineage lack specific proteins required for somatic hypermutation as occurs in the 
adaptive immune response. Therefore the repertoire of natural IgM is less 
diverse than that of conventional B cells. Natural IgM tend to have low antigen-
binding affinities that are compensated in part by high avidity due to the 
aforementioned pentameric structure of secreted IgM (sIgM) [10]. Although 
lacking the specificity of affinity-matured antibodies, the natural antibodies and 
the innate immune system can distinguish between self and non-self-antigens. 
Natural IgM is, therefore “oligo-specific” as opposed to “non-specific” as they are 
often incorrectly referred. Lastly, the innate system has enough genetic variability 
to encompass a broad spectrum of foreign antigens which ensures protection 
against the multitude of infections and malignant cells that challenge the 
multicellular organism in an average lifetime [13]. 
While the breadth data on the natural IgM response to cancer is still 
growing, the innate response to bacteria is much better understood. All data to 
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this point shows a striking similarity between the natural defense against bacteria 
and the response to new malignant (neoplastic) cells which strongly indicates 
that the humoral defense against neoplastic cells is based on innate immune 
mechanisms and not an Ag-induced affinity maturation process [10], [13], [14]. 
Studies have shown that antibodies that define new tumor-related molecules can 
be readily isolated from the sera of cancer patients. These natural IgM antibodies 
can be used in the investigation of new-tumor related structures and show 
potential for use in the development of new immunotherapies for cancer.  
The strongest previous argument against the use of IgM molecules has 
been that their sizeable pentameric structure will prevent vessel extravasation 
and tumor infiltration. However, recent studies into the tumor microstructure and 
microcirculation have shown that tumor vessels are generally thin-walled, 
chaotically arranged, and have greater permissibility for large macromolecules 
than do normal vessels [13]. The second argument against the use of 
monoclonal or polyclonal IgM antibodies has been studies showing the increased 
metastasis of melanomas through reaction with specific surface molecules 
present on IgM producing B-1 cells in vivo in genetically altered mouse models. 
However, the B-1 cell interactions involved in this study involved a separate 
receptor and cell to cell signaling that did not involve the IgM pentamer or surface 
molecule [15].  
The 2002 and 2003 studies by Brändlein et al. and the 2006 review by 
Vollmers and Brändlein all demonstrate strong arguments toward the further 
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investigation and therapeutic potential of natural IgM antibodies in the fight 
against cancer. The human monoclonal antibody SC-1 was found to induce 
apoptosis of gastric cancer cells in vitro and in vivo. Also, most natural antibodies 
found in the sera of cancer patients were of the IgM isotype with few IgG and IgA 
antibodies isolated. Even more interesting is that all natural antibodies studied in 
the following trials that were shown to be tumor-specific were of the IgM isotype. 
These tumor-specific natural IgM antibodies were strongly conserved structures 
with greater than 92.3%-100% H chain homology and greater than 97.2%-100% 
L chain homology. Finally, only one isolated antibody of the >5 studied showed 
weak reactivity with normal tissue [2], [13], [16], [17]. The data taken together 
speaks strongly for further investigation of the role of natural IgM in anti-tumor 
immune responses, and the best way to continue this line of inquiry is through 
further study of the immune cells responsible for their production: The B-
lymphocyte. 
B1 cells vs. B2 cells: the discovery of B cell subsets and lineage 
The immune system is categorized into the innate and adaptive immune 
systems distinguished by responding speed and specificity of reaction. The 
adaptive response consists of antigen-specific reactions through T lymphocytes 
and B lymphocytes and has a memory of past antigen exposure to enact a 
vigorous and rapid response to subsequent antigen exposure. The innate 
response which encompasses cellular and humoral elements provides immediate 
host defense and is highly evolutionarily conserved and has a rapid initial 
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response with a different spectrum of specificity from that of the adaptive 
response [18]. One goal of this project is to further elucidate the role of a 
particular B cell subset in tumor inhibition through natural IgM secretion or other 
effector functions. The B cell of interest is from a particular lineage of B cells 
called B-1 B cells that are functionally and ontologically distinct from B-2 B cells. 
It is reported that the antibodies secreted by B-1 B cells are “oligo-specific” 
and polyreactive to self-Ag. The term B-1 was initially proposed to describe a 
distinct fetal B cell development that is different from the B-2 cells generated in 
adult bone marrow [19]. The B-1 cells which only make up a small portion of B 
cells in murine spleen and lymph nodes are the major component of the B cell 
population in the peritoneal and pleural cavities [20]. B-1 B cells produce most of 
the natural antibodies in serum; B-1 B cells are involved mostly in T-independent 
antigen responses [21]. 
B-1 cells were first described as phenotypically different from B-2 cells 
through the identification of CD5+ B cells [19]. This phenotypic difference was 
initially thought to be a result of differentiation from other B cell subsets after 
initiation from a common progenitor cell. Evidence for this theory of a shared 
progenitor comes from evidence that B-2 cells can assume a B-1 cell phenotype, 
namely CD5 expression, under certain conditions, however this is highly disputed 
based on studies by Herzenberg’s group in monitoring entry of bone marrow-
derived cells into the B-1 pool in adults and demonstrating the rarity of this 
phenotypic alteration of the B-2 cell [20]. Hayakawa and Hardy proposed a 
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schematic for the distinction between B-1 and B-2 cell development that further 
alludes to signaling involved in the formation of three distinct B cell subsets: B1a, 
B1b, and B2 cells (Figure 1, taken from [4]). This schematic and the paper 
surrounding describes some differences in fetal pro-B cells that preferentially 
produce B-1 cells and adult pro-B cells that preferentially produce B-2 cells with 
some possible contributions of B-1b cells to the B-1 compartment. 
 
Figure 1: B-1 and B-2 cell development in fetal versus adult mice 
Hayakawa and Hardy proposed this schematic in a 2000 commentary to demonstrate how both 
lineages while distinct go through similar stages from Pro-B cell to immature B cell (Imm-B) to 
transitional (µ
++
δ
+/++
) and how later distinctions and naming can be made regarding phenotype (B-
1a, B-1b, B-2) or development (fetal/adult, Type-I/Type-II, B-1/B-2) [4]. 
A significant distinguishing finding is that fetal pro-B cells lack the enzyme 
terminal deoxynucleotidyl transferase (TDNT) which catalyzes the addition of 
nucleotides to the 3’ terminus of DNA without a template and is a principal 
contributing factor to µ-heavy chain diversity. This lack of TDNT in Fetal Pro-B 
cells leads to a difference in initial heavy chain diversity when compared to the 
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high expression TDNT adult Pro-B cells which will ultimately have a broader, 
more diverse µ-heavy chain repertoire. Therefore B-1 cell-derived IgM antibody is 
germline encoded. Further distinctions in antibody repertoire between B-1 and B-
2 cells are found in the selection and tolerance mechanisms that select each cell 
population. After the surface expression of the B cell receptor (BCR) the fate of 
naïve B cells is critically determined. BCR signaling due to autoreactivity in 
immature B-2 development leads to tolerance induction, anergy, deletion, or 
receptor editing and light chain replacement. In B-1 cells of the CD5+ phenotype, 
there is extensive evidence for positive selection for low-affinity autoreactive B 
cells and the critical involvement of self-antigen in the generation of natural B 
cells and serum natural autoantibody [4]. 
The theory of a separate B cell lineage for peritoneal and pleural B-1 cells 
is still under debate. However, some experiments reviewed by Leonore A. 
Herzenberg in 2000, including studies by Hayakawa and Hardy, were used to 
explore and defend the idea of separate developmental lineages between CD5+ 
B-1 and B-2 cells. The basis of Herzenberg’s defense was tripartite: 1.) there are 
distinct progenitors for B-1 and B-2 cell, 2.) these progenitors express their 
original commitment in co-transfer recipients, and 3.) these cells have distinct 
developmental patterns [20]. In various studies, it is seen that B-2 progenitors in 
adult bone marrow maintain B-2 cell commitment in situ and adoptive transfer 
studies involving B-cell depletion and radiation chimeras. Also, the depletion 
chimeras show that the proportion of B-1 cells derived from endogenous 
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progenitors is always small and has little input from the adult bone marrow 
progenitors that continually replenish the B-2 population. Further, radiation 
chimeras made by reconstituting with adult bone marrow and allotype-congenic 
fetal liver demonstrate B-2 cell derivation from both bone marrow and fetal liver 
sources, whereas B-1 cells are exclusively derived from fetal liver progenitors. 
This critical distinction is not due to regulatory mechanisms that obscure B-1 
progenitor activity as bone marrow does not contain inhibitors that mask pro-B-1 
activity nor does fetal liver contain special cells required to support B-1 cell 
development. The B-1 and B-2 developmental pathway differences are clear 
from studies demonstrating fetal liver restriction to B-1 cell generation as well as 
differences in intracellular protein expression between fetal liver and bone 
marrow pre-B cells. The final pathway distinction between B-1 and B-2 cells is 
the early expression of Ig which precedes MHC class II expression in fetal liver 
cells that generate B-1 cells and occurs at a similar time as IgD and CD5 
expression; in contrast MHC class II expression occurs early on pre-B cells in 
adult bone marrow and precedes surface Ig expression on B-2 cell progenitors 
[20]. Altogether the phenotypic, functional and co-transfer studies provided ample 
justification for assigning B-1 and B-2 cells to separate lineages even without 
specific identification of a B-1 cell progenitor. Regardless, continued research 
into B-1 cells and their functional and developmental processes lead to the 
discovery of a B-1 cell specific progenitor by Montecino-Rodriguez et al. in 2006, 
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and while this is not indisputable proof of separate lineages, it adds to the 
growing evidence of distinct developmental pathways for B-1 and B-2 cells. 
Before differentiation into the distinct functional subsets, B cells begin from 
hematopoietic stem cells. During embryonic life, the fetal liver is an important site 
of early B cell production, and after birth and throughout adult life, the geographic 
location of B cell progenitors switches to the bone marrow. Hematopoietic stem 
cells differentiate immature B cell progenitors (Figure 1), here referred to as pre-
pro-B cells identified phenotypically based on surface presentation as 
CD45R(B220)+CD43+AA4.1+CD19-Ly-6C-. These pre-pro-B cells then mature 
into CD45R+CD19+CD43+AA4.1+ pro B cells from which development continues 
following heavy chain expression and functional rearrangement. Some pre-B 
cells migrate to the spleen where they undergo final maturation into follicular 
(FO) or marginal zone (MZ) B cells which contribute to and are main effectors of 
adaptive immunity; these cells are classic B-2 cells. B-1 cells which include the 
complementary but functionally distinct B-1a and B-1b populations are derived 
from committed progenitors that are preferentially produced during fetal 
hematopoiesis. A specific progenitor identified in by Montecino-Rodriguez et al. is 
redefined as Lin-CD45Rlo-negCD19+ and is potentially the B-1 cell-specified 
progenitor. Transplantation experiments showed that this low CD45R, CD19 
expressing progenitor cell efficiently generates functional sIgMhighCD11b+CD5+ 
(B-1a) or sIgMhighCD11b+CD5- (B-1b) cells, but not sIgM+CD11b- B-2 B cells in 
vivo. The efficient generation of B-1 cells from these progenitors indicates that 
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the Lin-CD45Rlo-negCD19+ progenitors are restricted to B-1 B cell development. 
This B-1 B specified pro-B cell line also responds to thymic stromal 
lymphoprotein (TSLP) which is a property previously ascribed to only fetal B cells 
[22]. However, TSLP was found not to be required for B-1 B cell development 
although there is a possibility that TSLP signaling is involved in some phase of 
their development or homeostasis. Further experimentation revealed that this 
lineage-specific progenitor cell was the earliest recognizable B lineage progenitor 
in fetal bone marrow and fetal liver which collectively supports the idea of a 
distinct B-1 B cell progenitor and the accompanying B-1 B cell developmental 
pathway models. The final proof designating the Lin-CD45Rlo-negCD19+ 
progenitors as B-1 specific is the finding that initiating differentiation of these cells 
produces VH11 and VHQ52 Igh heavy-chain gene segments associated with anti-
phosphorylcholine (anti-PC) antibodies that are specifically secreted by B-1 B 
cells [22]. Conclusive evidence is therefore present for the identification of Lin-
CD45Rlo-negCD19+ pro-B cells as being B-1 cell lineage-restricted progenitors. 
Taking into account B-1 B cell progenitors discovered by Montecino-
Rodriguez et al. and based on previous transfer experiments and work 
demonstrating the requirement for antigen-stimulation for CD5+ B-1 B cell 
generation, a 2006 paper by Richard R. Hardy proposes a renewed model for 
development that takes into account CD5 expression induced by BCR signaling, 
and Ag-induced receptor editing or apoptosis. This unified model for B cell 
development is shown in Figure 2 (taken from RR Hardy[19]). 
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Figure 2: Richard R. Hardy’s unified model for B cell development and the generational 
pathways of four functionally distinct B cell subsets. 
B-1/fetal and B-2/adult development generate four functionally distinct subsets: B-1a, B-1b, MZ, 
and B-2/follicular (FO). In B-1 development strong BCR-mediated signaling generates B-1a cells 
while intermediate strength signals produce B-1b and MZ B cells, and the weakest BCR signaling 
results in receptor editing or apoptosis. In contrast, in B-2 development, strong BCR signaling 
results in receptor editing or apoptosis, while intermediate signals can again produce B-1b and 
MZ B cells, while the weakest BCR self-antigen signaling generates the B-2/FO B cells. BCR 
signaling levels are indicated by color (blue, green, yellow, and red; weak/negligible to strong) 
[19]. 
This model and BCR signaling regulated developmental pathway 
described by Hardy reconciles data showing the different function and antigen 
repertoires expressed in B-1 and B-2 cells. Fetal or B-1 development produces B 
cells that must be selected by self-Ag stimulation through strong BCR signaling 
before entry into the B-1a B cell pool. The B-1 development pathway selectively 
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halts B-1 cell maturation if the cell exhibits weak BCR signaling, is not exposed to 
an antigen, or if BCR signaling is handicapped in some way. This selection 
process produces B-1 cells that are polyreactive to self-antigen and highly 
conserved sequences that promote a first line antibody response that is part of 
the natural immunity. In contrast, adult or B-2 development produces B cells that 
experience deleterious consequences upon Ag encounter inducing apoptosis or 
anergy in B-cells that experience strong BCR signaling resulting in the B-2/FO 
cell populations that are unreactive to self-antigen and contribute to adaptive 
immunity. In both pathways, intermediate BCR signaling may promote B-1b and 
MZ B cell generation and entry into those populations which suggest a hierarchy 
of selection and overlapping but non-redundant functions for each cell type [19], 
[23], [24]. 
B cell subsets and their functional roles in immune responses 
The discovery and identification of distinct B cell subsets and the 
individual development pathway of each subset have resulted in greater 
understanding of the tiered nature of the immune system and the division of labor 
used by the immune system in defending against and removing invaders. While 
the immune system is comprised of much more than just B cells and the subsets 
discussed above, we are most interested in learning more about how these B cell 
subsets fight invading pathogens and how they each work individually and 
together in immunity. 
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As mentioned above the immune system is made of many different types 
of cells that differ even more than the B cell subsets. Mast cells, phagocytes, 
granulocytes, dendritic cells, and T cells are all essential parts of the full immune 
response. There is a considerable degree of crosstalk between the cell types, 
and in fact, T cells control much of the B cell activation and response through 
antigen presentation to surface Ig receptors, co-stimulation through CD40-CD40 
ligand interaction, and cell recruitment through chemokine and cytokine 
secretion. However, the discovery of Activation-induced cytidine deaminase 
(AID) a critical enzyme present in B cells that aids in RNA editing and helps 
increase repertoire diversity by allowing Ig class switching and somatic 
hypermutation lead to the realization that B cells can identify a greater variety of 
Ag epitopes than T cells which can only use VDJ recombination. This recognition 
of B cell antibody diversity in turn guided research towards finding ways in which 
B cells are regulated in a T-independent manner. The T-independent immune 
response, therefore, does not require T cell stimulation and is carried out 
predominantly by B-1 and MZ B cells while the classic T-dependent immune 
response predominantly involves conventional B-2 B cells [25]. 
B-1 cells have previously been described as secreting large amounts of 
natural IgM antibodies, even before antigenic stimulation, that becomes a crucial 
part of the innate immune system. Consequently, these B-1 cells are essential 
secretors of intestinal/mucosal IgA after migration to gut-associated lymphoid 
tissues (GALT). Closely related splenic marginal zone (MZ) B cells which are 
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phenotypically distinct from B-2 B cells through their higher expression of 
complement receptors and IgM also fall into the category of responding to 
pathogens in a T-independent manner. These cells are thought to be positively or 
negatively regulated through secretion of B lymphocyte stimulator (BLys) or 
through receptor engagement of Programmed Death 1 (PD-1) to one of its 
ligands, PD-1 engagement (to be discussed in greater detail later) [25]. 
Ultimately we begin to see that while B cells play a prominent role in the whole 
immune system regulation, activation, and defense, they also have individual 
roles that may not require other immune cell or component activation before 
eliciting a response. 
The most natural distinction is made between B-1 and B-2 cells regarding 
their roles in the immune response. After most pathogenic Ag stimuli there are 
two types of circulating IgM found in the serum: Natural IgM secreted by B-1 cells 
and antigen-induced Ag-specific IgM secreted by B-2 cells. Both IgM types are 
pentameric or hexameric and can bind the multimeric antigens and activate 
complement which makes natural and Ag-induced IgM a potent early defense 
mechanism against pathogens. A study on the effect of these two types of IgM 
using influenza virus carried out by Baumgarth et al. using mice that lack the 
ability to secrete IgM (sIgM-/-) and various radiation chimeras that alter between 
B-1 cell IgM secreting or B-2 cell IgM secreting ability demonstrated that both 
IgM types are necessary for optimal immune protection from Influenza virus 
infection. Specifically, Baumgarth et al. showed that sIgM-/- mice are more 
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susceptible to death than wild-type mice following infection and that even 
surviving sIgM-/- mice have a significant (P<0.05) increase in viral load. The 
group further demonstrated that the mechanism through which the IgM types act 
is through efficient induction of virus-specific IgG and that the lack of serum IgM 
in sIgM-/- mice did not affect the CD4+ T cell response. The group went on to 
demonstrate that both B-1 secreted IgM and B-2 secreted IgM is necessary for 
full IgG response and that one type of serum IgM alone does not confer 
immunity. The cross-reactive B-1 secreted natural IgM (nIgM) provides an 
essential first-line defense and functions before Ag-specific IgM becomes 
available, but the B-2 secreted virus-induced IgM provides additional protection 
and functions concurrently with the nIgM to promote IgG response [24]. In this 
way, we see how the B-1 and B-2 cells provide non-redundant, concerted 
protection against viral pathogens even when secreting the same Ig class 
antibodies. 
B-1 and B-2 cells have further differentiable roles when looking at their 
capacity as antigen presenting cells (APCs). Antigen-presenting cells play a huge 
role in T cell priming and differentiation, and while the traditional understanding of 
the immune system places dendritic cells as the primary immune APCs, the B 
cells are also potent APCs and have potent effects in T cell priming, 
differentiation, and tolerance. In a study carried out by Zhong et al. B-1 and B-2 
cells were found to have strikingly different consequences resulting from antigen 
presentation. Peritoneal B-1 cells were found to promote vigorous proliferation of 
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CD4+ T cells and induced excess secretion of Th1 cytokines while splenic B-2 
cells promoted a much more blunted CD4+ T cell proliferation and lower levels of 
Th1 cytokine secretion. Also, splenic FO B-2 cells produced a strong induction of 
regulatory T cells (Tregs) as assessed through Foxp3 expression. The FO B-2 
cells were the pinnacle of a hierarchy of potency in Treg induction with the most 
robust tolerance effects, followed next by peritoneal B-2 cells which had a 
weaker Treg induction, and lastly by peritoneal B-1 cells which regardless of IL-
10 (an immunosuppressive/anti-inflammatory cytokine) presence converted very 
few T cells towards Treg induction. The strength of B-1 stimulation as a 
professional APC, when compared to B-2 cells, was further proven by findings 
that while B-2 cells promoted Treg induction when co-cultured with Foxp3-CD4+ T 
cells and proper cytokines, the peritoneal B-1 cells under similar conditions 
promoted Th17 induction as readily as previous Th1 induction. This Th17 
generation mediated by B-1 cells is a possible factor in the inflammatory 
response against tumors [26]. The vast difference in T cell induction seen by the 
B-1 and B-2 cell subsets is further evidence of the tiered nature of the immune 
response and the fascinating division of labor in the regulation of immune 
responses. 
Differences in the immunologic role of B-1 and B-2 cells at this point seem 
evident as they represent distinct phenotypic and ontogenic subsets. However, 
further study into the B-1 cell shows even more distinction in the roles of B-1a, B-
1b, and even MZ B cells. The B-1 cell subset and MZ B cells are much closer in 
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relation and function than B-1 and B-2 cells. Both B-1 and MZ B cells express 
CD-9 which is absent on FO B-2 cells and is possibly responsible for the homing 
characteristics of the MZ cells to the splenic marginal zones and of the B-1 cells 
to the peritoneum or pleural body cavities. B-1 and MZ B cells both undergo BCR 
signaling selection and enrichment and both share similar proliferative signals 
and are part of the early response to pathogens. However, B-1 cells and MZ B 
cells share key distinctions including responsiveness to Fas-induced apoptosis 
and expression of CD5. B-1 cells are classically differentiated by CD5 expression 
and when compared to MZ B cells or FO B cells and are less responsive to anti-
IgM induced apoptosis and undergo dramatically fewer Fas upregulation and 
subsequent apoptosis induced by BCR crosslinking [27]. These similarities and 
differences are elaborated in Table 1 (taken from Martin and Kearney [27]). 
Further work in pyk-2 deficient mice (mice without splenic marginal zones and 
therefore a diminished MZ B cell compartment but standard peritoneal B-1 cell 
compartment), done by Martin et al. demonstrated the layered effect on immunity 
of the presence of B-1 and MZ B cells. Martin et al. showed that while both B-1 
and MZ B cells generate large numbers of polyclonal IgM secreting plasma cells 
in response to classic T-independent antigens, there is a functional and 
geographic heterogeneity in the responses. Mainly, peritoneal B-1 cells are the 
predominant IgM secreting cells in TI responses, but in transfer studies where 
MZ cells are made to out-populate the B-1 cells, there is negative feedback or 
downregulation of B-1 cell generated plasma cells. Lastly, the peritoneal B-1 cells 
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are noticed to produce the dominant IgM response to TI antigens when the Ag is 
introduced through the intraperitoneal (i.p.) route. However, MZ B cells take over 
and have a more substantial effect when the Ag is introduced intravenously (i.v.). 
The different response to inoculation routes shows that the B-1 subset can 
efficiently clear locally encountered antigen, but as systemic and blood-borne 
spread occurs MZ B cells in the spleen are rapidly recruited into the initial natural 
IgM response [28]. This distinction of B-1 and MZ B cell response represents a 
geographically segregated redundancy that confers additional early protection 
against antigens. 
Table 1: Characteristics of B1 cells, MZ B cells, and FO/B-2 B cells 
This table is taken from a review by Martin and Kearney. This table shows that while B-1 and MZ 
B cells share several key phenotypic and functional characteristics, they are still readily 
differentiable past geographic segregation. The full table includes sources cited by Martin and 
Kearney [27, p. 1] 
 
It is important to note that under certain circumstances, for example, the 
elevation of chemokine CXCL13 concentration outside peritoneal cavity or LPS 
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stimulation in the peritoneal cavity, B-1 cells readily exit peritoneal cavity into the 
bloodstream [29], [30], [31, p. 13], [32]. 
B-1 cells have thus far been described as being the primary source of Ag-
specific antibody in TI responses as well as being essential players in the early 
humoral response through their secretion of natural IgM antibodies. The B-1 
compartment is functionally distinct from both the B-2 and MZ B cell subset and 
can be further distinguished by phenotype, anatomical location, and self-
renewing capacity.  
Now, it is necessary to further divide B-1 cells into B-1a(CD5+) and B-
1b(CD5-) subsets based first on surface expression of CD5 and next through 
different functionality in the immune response. A study conducted by Haas et al. 
using CD19-/- mice which are deficient in CD19 expression and therefore have 
impaired development of the B-1a subset and hCD19Tg mice which overexpress 
CD19 and augment B-1a development. These mice, when exposed under 
variable conditions to S. Pneumoniae, demonstrated vastly different survival 
rates and immune responses. The CD19-/- mice were most susceptible to 
infection following exposure than hCD19Tg or wild-type mice due to the CD19-/- 
mice’ lack of B-1a cells, elevated proportion of B-1b cells, and consequent lack of 
natural antibody protection, however after immunization with heat-killed S. 
Pneumoniae these mice were able to generate S. Pneumoniae specific antibody 
and were better prepared for subsequent infection or exposure. The hCD19Tg 
mice which had elevated proportions of B-1a cells and reduced proportions of B-
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1b cells had normal or elevated natural IgM titers in comparison to wild-type and 
CD19-/- mice and therefore equally susceptible to infection as naïve wild-type 
mice. However, the hCD19Tg were unable to transfer immunization to adaptive 
immunity and S. Pneumoniae specific Ab (IgM or IgG) production following 
immunization and therefore more susceptible to infection with pneumococcal 
polysaccharides (PPS) than wild-type or CD19-/- mice. The study demonstrates 
the division of labor within the B-1 cell compartment and the role of B-1a cells as 
the primary natural antibody producers, while B-1b cells are independently 
responsible for protective anti-PPS responses [23]. This study paints a complete 
picture of the B-1 cell compartment and the way natural immunity is carried to 
adaptive or Ag-specific immunity by the B-1 cell. 
The functional roles of the B cell are extensive, stemming from the various 
subsets of B cell and their ontogenetic and phenotypic differences. The B cell is 
classically divided between B-1 or natural immune B cells and B-2 or adaptive 
immune B cells. However, further distinctions can be made that separate B-1 
cells from MZ B cells based on proliferative response rates and geographic 
homing in the body. Even within the B-1 compartment, we see that B-1a cells are 
the potent natural antibody secreting cells while B-1b cells can be equally 
responsible for natural IgM secretion and efficient communication of pathogen 
and generation of antigen-specific and adaptive immune response. Ultimately, 
we see that the B cell subsets work together to form a layered, non-redundant 
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system that is capable of responding to various pathogens in a whole immune 
system and a T cell independent way. 
Programmed Death 1 and Ligand 2: B cell-mediated regulation 
The programmed death 1 receptor (PD-1) was initially discovered in T 
cells undergoing cell death [33]. Since its discovery, numerous studies have 
gone into elucidating its role in cell to cell regulation of immune responses, and 
despite the moniker, the receptor has little to do with cell death [34]. A study of 
the PD-1 receptor on the surface of stimulated lymphocytes by Agata et al. 
demonstrated that the PD-1 receptor is a 50-55 kDa membrane protein with 
inducible expression on the surface of stimulated murine T and B cells. This early 
study characterized the receptor as heavily glycosylated and revealed that 
expression of PD-1 alone did not trigger apoptosis. Further, the study revealed 
that resting lymphocytes exhibited limited expression of PD-1 and only after 
stimulation with specific antigens acting through T cell receptors (TCRs) and 
BCRs was the PD-1 receptor expressed on the surface of activated cells [35]. 
Thus an initial understanding of PD-1 was born. However further research was 
needed before the discovery of its ligands Programmed Death Ligand 1 (PD-L1), 
and Programmed Death Ligand 2 (PD-L2) was accomplished. 
The PD-1 receptor is part of an Ig superfamily and is a CD28 homolog that 
has a cytoplasmic region containing both an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) 
[36]. In vitro studies of PD-1 mutants demonstrated that the tyrosine residue in 
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the ITSM is essential for the function of PD-1 while the ITIM tyrosine is not [37]. 
The structural similarity of PD-1 to cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4), another inhibitory receptor commonly found on activated T cells, leads 
to the search for a PD-1 ligand that may be part of the B7 family of molecules. 
The ensuing search lead first to the discovery of B7-H1 (referred to as PD-L1) 
and then to the discovery of B7-DC (referred to as PD-L2). A study by Latchman 
et al. presented the initial characterization of this second PD ligand. The 
Latchman study found PD-L2 to have 70% homology between murine and 
human and 21-27% homology to PD-L1 with similar structural motifs and PD-1 
binding region [38]. Regardless, the amino acid sequence surrounding the ITSM 
is wholly conserved between mice and humans which establishes its functional 
importance [37]. There is differential expression of PD-L1 and PD-L2 throughout 
the body in both mice and humans, and PD-L2 showed delayed induction 
kinetics when compared with the up-regulation of PD-L1. While both PD ligands 
produced a marked decrease in T cell proliferation, PD-L2 was found to 
significantly decrease the production of crucial stimulatory cytokines in CD4+ T 
cells. A key distinction between the two ligands was the greater inhibitory effect 
of T cell proliferation and cytokine production by PD-L2 at lower antigen 
concentrations when compared with PD-L1. The ligation of PD-1 with its ligands 
was shown to recruit tyrosine phosphatase SHP-2 to PD-1 and promote cell 
cycle arrest of stimulated CD4+ T cells. However, no increase in cell death was 
observed [38]. This study demonstrated the similarities in structure and inhibitory 
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function of the PD ligands on activated T cells and pushed further interest into 
the specific roles each ligand plays in immune system regulation. 
Understanding the role of PD-L1 and PD-L2 in receptor engagement and 
immune regulation requires an understanding of ligand and receptor expression 
throughout the body. A study by Yamazaki et al. demonstrated the inducible 
expression of PD-L2 on isolated macrophages and dendritic cells and a complete 
lack of inducible or constitutive expression on splenic B cells of CD4+ or CD8+ T 
cells. PD-1 and PD-L1 expression were found to be inducible on all studied 
immune cell subsets in variable amounts related to the cell type and stimulatory 
factors used, exceptions being a lack of inducible PD-1 expression on 
macrophages and dendritic cells. Further, the expression of PD-1 on splenic B 
cells was significantly increased following co-stimulation by anti-IgM and anti-
CD40 which suggested preferential expression of PD-1 by B cells involved with 
CD40L expressing T helper cells [36]. While still incomplete, the understanding of 
inducible PD-L2 expression by APCs was necessary for the growing 
understanding of PD-L2 as an immunoregulatory molecule. 
PD-1 expression in B cells is of particular interest in this study, and before 
elaborating the role of PD ligand, it is necessary to note the dynamic expression 
of PD-1 on stimulated and naïve B cells. In B cells PD-1 expression is triggered 
through engagement of the BCR but does not require continued receptor 
engagement for continued PD-1 surface presentation. Additionally, several 
common immune danger signals including lipopolysaccharide (LPS), CpG 
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Oligodeoxynucleotide (ODN), and several inflammatory cytokines act to 
downregulate PD-1 expression on B cells through various mechanisms. 
Specifically, LPS confers its down regulatory effects through TLR4, CpG ODN is 
found to act through MyD88 to reverse the elevated PD-1 expression produced 
by BCR engagement, and IL-4 acts through STAT6 mediated pathways to 
reduce the elevated PD-1 expression to similar levels as the previous two danger 
signals. Additionally, IL-4 and CpG ODN were found to diminish PD-1 expression 
and remove the cell cycle arresting function of PD-L1 in inhibition B cell 
proliferation [39]. 
The specific study of PD-1 ligands demonstrated numerous differences in 
the role of PD-L1 and PD-L2 in immune regulation as well as kinetic differences 
in binding properties. PD-L2 was found through Scatchard plot analysis to have a 
2-6 fold higher binding affinity to PD-1 than the PD-L1/PD-1 interaction. 
Subsequent surface plasmon resonance analysis clarified the ligand binding 
kinetics and showed 3-7 folds slower dissociation kinetics of PD-L2/PD-1 binding 
when compared to PD-L1/PD-1 binding. Ultimately this proved a higher affinity of 
PD-L2/PD-1 interaction than the PD-L2/PD-1 binding [40]. The study of binding 
kinetics was one of the myriad studies into the specific role either ligand has 
regarding immune regulation. PD-1 dysregulation and PD-1 deficiencies in mice 
are shown to produce a variety of autoimmune disorders including lupus-like 
autoimmune disorders, dilated cardiomyopathy, acute type 1 diabetes in non-
obese diabetic mice, and bilateral hydronephrosis in PD-1 and FcγRIIb deficient 
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mice. PD-1 and ligand interaction is also crucial in feto-maternal tolerance and 
has a possible function in transplantation immunity. An exciting avenue for 
cancer therapy involves the expression of PD-L1 and PD-L2 on various tumor 
cells and the possible use of these ligands by tumor cells to evade immune 
detection and eradication. It is suggested that PD-1-PD-L blockade may help the 
host immune system identify and eradicate these tumor cells [41]. Overall, the 
expression of PD-L2 is much more restricted than PD-L1. Classical thought 
suggests only inhibitory roles in the PD-1-PD-L interaction. However, further 
study has demonstrated a specific PD-L2 IgM that has dendritic cell activating 
capability and enhances migration to lymph nodes. Additionally, PD-L2 
deficiencies are shown to promote increased susceptibility to specific parasitic 
infections such as Leishmania Mexicana (L. Mexicana) [42]. Lastly, a study by 
Singh et al. demonstrated the opposing role of PD-L2 and PD-L1 in allergic 
disease and asthma. The Singh study demonstrated severely increased airway 
hyperresponsiveness and lung inflammation in PD-L2 deficient mice when 
compared with wild type, while PD-L1 deficient mice when challenged with 
similar allergens have reduced airway hyperresponsiveness and inflammation. 
The Singh study thus confirms the crucial role of PD-L2 in developing oral 
tolerance while also demonstrating the reciprocal role of PD-L1 and PD-L2 in the 
regulation of T helper 1 cell and T helper 2 cell responses [43]. 
The role of PD-L2 in immune tolerance and regulation is challenging to 
explain fully and is still under investigation. Previous studies have explained the 
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PD-1 and PD-L2 structure and binding kinetics, PD-L2 expression and induction 
in immune cells, and some roles of PD-L2 in immune regulation and disease. 
However, now we reveal a recently identified player in immune regulation: the 
PD-L2 positive B-1 cell. 
Introducing the L2pB1 cell a key player in cancer prevention 
The PD-L2 positive B-1 cell (L2pB1) is a specialized lymphocyte that is 
part of the subpopulation of B-1a cells. As aforementioned, the murine B cells 
can be divided into separate lineages characterized by distinct progenitors. B2 
cells are considered “conventional” B cells and consist of follicular (FO) and 
marginal zone (MZ) B cells. These B-2 cells are part of the adaptive immunity 
and home to spleen and lymph nodes in the body [20], [22]. B-1 cells have been 
shown to home to body cavities including the peritoneal cavity and pleural 
cavities. Additionally, B-1 cells are considered part of the innate immunity and 
are responsible for the naturally present secreted IgM (nIgM) in the bloodstream. 
B-1 cells can then be divided further into B-1a or B-1b B cells based on CD5 
presentation. B-1a cells are CD-5 expressing, are the dominant population of B-1 
B cells, and functionally are the source of nIgM antibody [44, p. 5]. The L2pB1 
cell is found to be a distinct B-1a cell. It represents a small part of total body B 
lymphocytes however it contributes to a large percentage of peritoneal B-1 cells, 
approximately 50-70% when analyzed via flow cytometry [5]. The L2pB1 cells are 
the major subpopulation of B-1a cells and are found predominantly in the 
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peritoneal cavity, but there are also small percentage of L2pB1 cells found in the 
murine spleen and lymph nodes [45]. 
The L2pB1 cell has many qualities that distinguish it from other B cell 
subsets and other PD-L2 expressing cells. Initially, PD-L2 expression was 
thought to be restricted to inducible expression in dendritic cells (DCs) and 
macrophages (MΦ) only [38]. However, upon further exploration of the role of the 
PD-1 pathway in disease mechanisms, a study by Zhong et al. published in 2007 
found expression of PD-L2 on a distinct subset of B-1 cells. The PD-L2+ cells 
were found predominantly in the mouse peritoneum with a smaller less distinct 
portion found in the spleen. Also, unlike PD-L2 expression in DCs and MΦs, the 
expression of PD-L2 in B-1 cells is not inducible. The B-1 cells found to express 
PD-L2 do so constitutively and the B-2 and PD-L2 negative B-1 (L2nB1) cells do 
not express PD-L2 and cannot be induced to do so under a broad variety of 
tested stimuli. Specifically, B-2 cells did not show any level of expression of PD-
L2 after greater than 2-day incubation with cytokines that are known to induce 
PD-L2 expression on DCs and MΦs, including interleukin-4 (IL-4), interferon γ 
(IFNγ), and granulocyte macrophage colony stimulating factor (GM-CSF). 
Additional stimuli that were tested and have known stimulatory effects in B 
lymphocytes include CD40L, Lipopolysaccharide (LPS), cytosine phosphodiester 
guanine oligodeoxynucleosides (CpG-ODN), and phorbol 12-myristate 13-
acetate (PMA)/ionomycin. The B-2 cells and L2nB1 cells tested with all stimuli 
were found never to begin expression of PD-L2; however, incubation with CpG-
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ODN, LPS, or CD40L converted substantial numbers of L2pB1 cells into L2nB1 
cells [5]. 
The mechanisms that generate expression of PD-L2 on B-1 cells have 
also been investigated to determine the functional role of the ligand for these 
cells. In DCs and MΦs the inducible expression of PD-L2 had been shown to 
involve the signal transducer and activator of transcription 6 (STAT6) pathway 
[46]. Examination of B cells from STAT6 knockout mice by Zhong et al. revealed 
regular numbers of peritoneal B cells without significant difference in population 
size of L2pB1 cells when compared with WT mice. This finding illustrated that 
PD-L2 expression in B-1a cells has little to no dependence on the STAT6 
pathway which is necessary for inducible expression in DCs and MΦs [5]. An 
investigation by Kaku and Rothstein utilized real-time PCR to determine that the 
mRNA transcript generated in PD-L2+ B-1 cells is different from the transcript 
generated in DCs and MΦs. The murine PD-L2 gene encompasses six exons 
with a start codon in exon 2 and a stop codon in exon 5. In DCs and MΦs all six 
exons were expressed following stimulation with IL-4. In direct contrast, L2pB1 
cells failed to express exon 1 which resulted in follow up investigation and 
determination of an intronic promoter sequence for the constitutive expression of 
PD-L2 [34]. The different transcription start site and promoter sequence location 
between the transcripts of inducible PD-L2 cells and L2pB1 cells lead to the 
belief that there is a distinct transcription factor that binds to the promoter region 
upstream of exon 2 in B-1 cells. Further research by Kaku and Rothstein 
 32 
determined that the Octamer binding proteins Oct1 and Oct2 are present in B-1 
cells and are responsible for binding the PD-L2 intronic promoter, but only the 
Oct2 protein constitutively binds the intronic DNA in B-1 cells but not in B-2 or 
L2nB-1 cells. Therefore the Oct2 protein is lineage specific to the pre-exon2 
intronic promoter sequence that allows constitutive expression of PD-L2 in B-1 
cells and not in B-2 or L2nB1 cells. Additionally, intronic promoter sequence and 
Oct2 protein are not utilized in DCs and MΦs which utilize a promoter sequence 
on exon1 of the PD-L2 gene and the STAT6 pathway for inducible expression of 
the PD-1 ligand [34]. 
It is necessary to note that the L2pB1 cell has an additional functional 
difference from the general B-1 cell population which makes it a potential target 
for therapies and further research. B-1 cells constitutively secrete nIgM that 
contributes to natural immunity. The 2007 Zhong et al. study found that L2pB1 
cells expressed substantially more VH11 and VH12 mRNA than did L2nB1 cells 
indicating that the Ig repertoires for the subpopulations skew towards different 
antigen specificities. These subsets did not differ in expression of several other 
VH gene segments which were used as a control. Additionally, the L2pB1 cell 
population was found to bind specifically to phosphatidylcholine (PtC); the L2nB1 
cell population did not bind PtC to the same large extent. Ultimately it was 
reasoned that PD-L2 expression on B-1 cells identifies a B-1 subset whose Ig 
repertoire is skewed towards VH11/VH12 variable heavy chain region gene usage 
and PtC binding [5]. 
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Additional functional differences of the L2pB1 cell were studied by Zhong 
et al. in 2009. A study of the L2pB1 cell in disease models in lupus-prone mice 
showed that L2pB1 cells preferentially secrete anti-double-stranded DNA (anti-
dsDNA) autoantibodies. Cell cultures grown with L2pB1 cells, L2nB1 cells, and 
B2 cells were stimulated with LPS for 5 to 7 days, and ELISA evaluation revealed 
that L2pB1 cell supernatant contained substantially higher levels of anti-dsDNA 
autoantibody and while the overall antibody levels are similar in all cell cultures 
the L2pB1 cell-derived antibody is enriched with dsDNA reactivity. This dsDNA 
autoantibody reactivity is present at elevated levels in disease models of 
systemic lupus erythematosus, and there was a dramatic increase in L2pB1 cells 
found in the circulation of lupus-prone mice. This correlation of L2pB1 cells that 
produced anti-dsDNA antibody to cross-reactivity with other lupus-related 
autoantigens provided insight into a possible disease mechanism for 
autoimmune dyscrasia. The L2pB1 cross-reactivity distinguished the L2pB1 cell 
as having an autoantibody repertoire that might take on a janitorial role around 
the body and the prevention of new tumor growth [47]. 
The Zhong study went on to show that L2pB1 cells were potent antigen 
presenting cells (APCs) even when compared to L2nB1 cells. The additional 
testing used sort-purified L2pB1 and L2nB1 populations that were co-cultured 
with sort-purified CD4+ T cells. The results showed that compared to L2nB1 cells, 
the L2pB1 cell stimulated three times more responding cell proliferation and the 
levels of key stimulatory cytokines such as IL-2 and tumor necrosis factor α 
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(TNFα) were higher after T cell co-culture with L2pB1 cells than after co-culture 
with L2nB1 cells and total B-1 cells. These results were confirmed for nominal 
antigen presentation and revealed L2pB1 cells to be more efficient APCs than 
L2nB1 cells. Lastly, the 2009 study demonstrated that L2pB1 cells preferentially 
switch to IgG1 or IgG2b isotypes when stimulated with IL-21, however little to no 
L2pB1 cells switched to IgG2a isotype [47]. 
Further research by Guo and Rothstein determined the Ras guanyl 
nucleotide releasing protein (RasGRP) 1 dependence of B1a cells and how this 
RasGRP1 dependence relates to the function of L2pB1 cells and the 
autoantigen-specific receptors. RasGRP1 is essential for the transduction of 
weak signals and therefore is essential to the positive selection that B-1a cells 
undergo during maturation. It was found that B-2 cells generate mostly RasGRP3 
and little RasGRP1, but they are reliant only on RasGRP3 and are unaffected by 
removal of the RasGRP1 in deficient mice. In comparison, the B-1 cells express 
only RasGRP1 and are severely impaired and virtually eliminated in RasGRP1-
deficient mice. RasGRP1 deficiency principally affects L2pB1 cells even though 
the expression of the RasGRP1 protein is similar in L2pB1 and L2nB1 cells. 
Because L2pB1 cells are enriched with autoreactive BCR Ag receptors that 
produce weak BCR signals, the RasGRP1-dependent signaling is indispensable 
for transduction and positive selection of these weak signals in the early 
development of L2pB1 cells [48]. 
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Ultimately, L2pB1 cells are a special population of B-1a cells that express 
numerous hallmark B-1 cell characteristics. L2pB1 cells exhibit unique 
constitutive expression of PD-L2 which utilizes RasGRP1 and Oct2 promoter 
binding protein and an intronic promoter region [34, p. 2], [48]. The L2pB1 cells 
exceed L2nB1 cells in expression of a germline-encoded autoreactive Ig 
repertoire that undergoes specific isotype switch to IgG1 and IgG2b upon 
cytokine stimulation with IL-21 [47]. Furthermore, L2pB1 cells exhibit highly 
efficient APC activity, an Ig repertoire skewed towards PtC binding and utilization 
of VH11/VH12 Ig heavy chain gene expression [5]. Lastly, elevated levels of 
L2pB1 cells are associated with autoimmunity in murine models, and the 
identification of PD-L2 polymorphism linked to human systemic lupus 
erythematosus infers a connection to autoimmune disease [45]. These distinct 
properties of the L2pB1 cell make it a fascinating target for study. The 
possession of an autoreactive Ig repertoire and the ability of the cells to migrate 
from body cavities make the cell population an interest for research as an 
antitumor actor that identifies new tumor cells and efficiently presents the 
autoreactive antigen to other immune cells in a coordinated innate and adaptive 
immune response. 
B cells and cancer: 3D spheroids as a better in vitro tumor model 
To study the effects of immune cells on cancer cells, a reproducible assay 
in which to test the co-culture cytotoxicity of various immune cell treatments on 
established cancer cell lines must be developed. Traditionally, in vitro co-culture 
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assays have been completed with cancer cells grown flat in 2D monolayer and 
subsequent addition of immune cells. Monolayer cultures offer an inexpensive 
and straightforward strategy of growing cells with good viability; however, they 
lack many of the complex factors found in the in vivo tumor microenvironment [7]. 
Still, it is necessary to perform in vitro experiments to provide initial confirmation 
of a hypothesis before moving forward with costly in vivo experiments on model 
animals.  Because of the experimental uncertainty that comes from utilizing 
imperfect models of in vitro tumor growth, there have been many advances made 
in the establishment and analysis of three-dimensional cell culture. Currently, 
multicellular tumor spheroids (MCTS) are established as simple to create and 
incredibly useful in modeling in vivo small tumor establishment and avascular 
tumor growth [49]. 
For many years the gold standard of cellular cytotoxicity assay has been 
heterogeneous co-culture of cells in two-dimensional monolayers. Monolayers 
provide an easy to set up experimental system that provides good viability of 
target cells in culture [7]. Additionally, monolayers are quick, inexpensive, and 
provide for high throughput, easily reproducible assays. Still, the limitations of the 
2D monolayer in adequately modeling the in vivo microenvironment of growing 
tumors are substantial. Monolayer cultures lack stroma, extracellular matrix 
(ECM) and interstitial fluid, and are kept in much more hospitable growth 
conditions than are found in vivo [7]. Also, cell-cell and cell-matrix interaction are 
crucial in understanding intercellular signaling and have relevance in the action 
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and penetration of treatments or physiologically occurring elements [7]. These 
limitation found in 2D culture outweigh the benefits that these experimental 
techniques provide when taken in comparison to the use of 3D tumor spheroids. 
The advantages of 3D cultures over 2D monolayers are multifactorial. 
Cells grown in monolayer often lose tissue-specific properties that are better 
retained in 3-D culture due to the tight communication network formed by the 
physiologically critical chemical and biological signals of cell-cell and cell-matrix 
interaction [49]. A “classical” motivation for using MCTSs stems from the 
similarity of MCTS culture with the avascular phase of malignancy with micro-
metastases and with intercapillary micro-regions [7]. Additionally, it has 
repeatedly been observed that although cancer may display specific attributes in 
vivo, the cell lines in 2D culture are prone to different phenotypic characteristics 
which make an accurate pre-clinical selection of viable therapeutic candidates 
more difficult. In 3D culture, gene expression profiles much more accurately 
reflect the in vivo cancer cell that epigenetically responds to the physiological 
stresses it is placed under [50]. Ultimately we conclude that while 3D cultures are 
more difficult and costly to establish and maintain, they offer many significant 
advantages as a model for the study of cancer and cell to cell interactions when 
compared to typical monolayers. 
The growth of spheroid cell cultures is itself fascinating and complex, just 
as is the in vivo biology of the cancers we hope to model. Before the formation 
and compaction of cells into an MCTS, they must upregulate the expression of 
 38 
cadherin and chain-like ECM fibers. The ECM fibers provide a surface and 
pathway for initial cell aggregation while the upregulation of cadherin leads to 
homophilic cadherin-cadherin bonding which confers the strong cellular adhesion 
that is characteristic of MCTSs [49], [51]. The arrangement of cells grown in 
spheroids is suggestive of a diffusion-limited model; with the presence of 
proliferating cells on the periphery of the spheroid surrounding a region of viable, 
quiescent cells, and a central necrotic core formed from primary apoptosis and 
secondary necrosis [49], [52]. As spheroid size increases, apoptoses accumulate 
in the spheroid center and eventually form a necrotic core. However, the reason 
for necrotic core formation is multivariate, including contributions from tissue 
hypoxia, nutrient depletion, waste product accumulation, and low pH.[53] It is 
particularly interesting to note that the occurrence of necrosis precedes any 
measurable alteration of central oxygen tension, glucose, ATP, or lactate 
concentration and occurs even though these tumor cells modulate metabolic 
activity in response to nutrient deprivation or metabolite accumulation.[53] Figure 
3, taken from F. Hirschhaeuser et al., demonstrate a number of these spheroid 
characteristics and the gradients formed within the MCTS as it grows. The 
cellular architecture and state of the MCTS are highly dependent on spheroid 
size, so it is necessary to establish size or feature related beginning or endpoints 
when designing an experiment [50]. 
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Figure 3: Hirschhaeuser et al. ’s Spheroid Characteristics: a combination of spheroid 
cross-sections analyzed via different modalities. 
Median cross sections of various spheroids were collected and studied with various technologies 
including the tunnel assay which measures apoptosis via fluorochrome tagging of degrading 
DNA, bioluminescence imaging, histochemistry, and oxygen microelectrode probes. Together, 
these technologies and measurements enable understanding of the geometric arrangement of 
cell proliferation, viability, and micromilleu in large spheroids.[50] 
As previously indicated, gene expression profiles of cells grown in 3D 
spheroids are quite different in comparison to those grown in traditional 
monolayers [49]. A comparison of MCTS vs. monolayer culture of colon 
carcinoma cells found numerous differentially expressed genes related to tumor 
cell proliferation, survival, and resistance [54]. Not only, do gene expression 
profiles of spheroids differ from monolayer cultures, but they are also genetically 
closer to the parental cell line when compared to long-term monolayer cell 
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cultures. The genomic profiles of primary cells cultured as monolayers often 
deviate from the parental tumor profile, while spheroids are genetically more 
representative of the original tumor [49]. The fascinating biology of homogeneous 
spheroid culture is a large part of their prevalence over monolayer culture in vitro. 
Many reports indicate that treatments demonstrating strong effectiveness in 2D 
cultures can be expected to lose efficacy when transitioned to the 3D 
pathophysiological environment. Thus spheroids are an invaluable tool for 
accurate assessment of therapeutic value and negative selection to reduce 
unnecessary animal testing [50]. 
3D tumor spheroids were initially adapted to cancer research as an in vitro 
model that preserves the histomorphological and functional features of in vivo 
tumor tissue. This model was first applied to experimentation in radiotherapy and 
chemotherapy and has since been included in experimentation involving 
contemporary targeted approaches such as gene therapy and 
immunotherapy.[50] While great care must be taken to select the appropriate 
model to match the needs of each therapeutic investigation, homogeneous 
spheroid monocultures are the principal method used in the study of cancer 
immunology.[50], [52]  
Spheroid monocultures are currently formed in a variety of ways each of 
with have myriad benefits and drawbacks. The methods utilized in this research 
are the use of non-adhesive surface coated plastic wares and the hanging drop 
method. Other methods include the NASA rotary system, spinner flasks, micro 
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molding, 3D scaffolding, and many others that will not be discussed here [49]. 
Spheroid production through centrifugation compaction and use of plastic wares 
with non-adhesive surfaces are the simplicity of protocol, low cost, and easy 
scalability, but the variation in size and shape can be a major defect in planning 
appropriate assays. Production through use of hanging drop is also simple to 
perform and inexpensive and provides the additional benefit of well-controlled 
spheroid size, quick formation, better cell differentiation, and utility amongst 
multiple cell lines. The downsides of the hanging drop method are the labor-
intensive process and the difficulty in the scalability of production [49]. These two 
methods, the non-adhesive plate, and the hanging drop were utilized in the 
production of our B16F10 murine melanoma and MC38 murine colon carcinoma 
spheroids respectively. 
In this study, we have utilized the 3D spheroid as a better in vitro platform 
to grow our understanding of the anti-tumor effect of peritoneal L2pB1 cells 
utilizing a co-culture assay wherein immune cell suspensions are added to MCTS 
cultured from two distinct cancer cell lines. 
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SPECIFIC AIMS 
Studies have demonstrated the importance of Natural IgM in the innate 
immune response of multicellular organisms. Further studies have demonstrated 
phenotypic and ontological differences between B2 cells which have a higher 
function in adaptive immunity and B1 cells which home to body cavities in mice. 
The research presented herein is distinctly interested in the presence of L2pB1 
cells in the peritoneal cavity and the anti-tumor response of this subset of B1a 
cells. 
Previous work has compiled evidence of the tumor inhibition function of 
L2pB1 cells in a syngeneic immune treatment of an in vitro 2D tumor model (X. 
Zhong unpublished data). The purpose of this study is to confirm those findings 
of 2D cell culture inhibition of B16F10 melanoma cell growth by full syngeneic 
peritoneal immune cell washout as opposed to the reversion of this inhibition 
found in L2pB1 depleted immune treatments. This study proposes the use of a 
3D tumor spheroid model to prove the effects of L2pB1 inhibition of B16F10 
melanoma in vitro, and, also, aims to demonstrate the tumor inhibition effects of 
L2pB1 cells on the MC38 murine colon cancer cell line in 3D culture. 
To investigate the anti-tumor effects of L2pB1 cells, we will grow 3D tumor 
spheroids using either the B16F10 melanoma cell line or the MC38 colon 
adenocarcinoma and treat them with L2pB1 depleted or full peritoneal cavity 
washouts (PCW) and monitor growth over the course of 10 to 16 days from the 
day of treatment. Treatment will only begin after the establishment of the necrotic 
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core in the tumor spheroid, which occurs by day 4 or day 6 of growth and is 
dependent on cell line and spheroid formation method. Depletion of immune cells 
will be carried out in the inducible knockout model described in Lee et al. and 
confirmed with flow cytometry.[55] The effects of growth inhibition will be 
measured using an image cytometer and analysis of the immune cell treatment 
effects on the MCTS cross-sectional area. Cellular cytotoxicity assays will be 
carried out as endpoint procedures to analyze the relative immune effect on 
necrotic core size. Additionally, a total mouse IgM ELISA will be conducted on 
stimulated and unstimulated immune cell collections, and the average amount of 
IgM produced will be measured in an attempt to identify a mechanism for the 
hypothesized inhibitory effect. Lastly, a univariate statistical analysis will be 
carried out to determine whether there is a significant difference made in tumor 
inhibition effect of immune cells when depleted of L2pB1 cells or left whole. 
We hypothesize that the L2pB1 cell plays a vital role in the 
immunosurveillance and response to cancers. This role will be demonstrated by 
seeing a robust inhibition of spheroid growth in full immune cell treatments and a 
reversion of that anti-tumor effect in L2pB1 cell depleted immune treatments. 
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METHODS 
Animal model and housing 
All experiments were approved by the Boston University Medical Campus 
Institutional Animal Care and Use Committee (IACUC). Animals were cared for in 
compliance with the “Principals of Laboratory Animal Care’ formulated by the 
National Society for Medical Research and the “Guide for the Care and Use of 
Laboratory Animals.” CD-19-Cre+/- PTZD+/+ mice on a C57BL/6 background, 
henceforth referred to as red mice, were generated and bred in the animal facility 
at Boston University School of Medicine. All mice were cared for in an ABSL-2 
room with standardized circadian cycles and diet. Sterile cages and equipment 
were used when handling mice at all times. These mice had the following genetic 
alterations: (1) expression of TdTomato only in PD-L2 expressing cells, (2) 
Diphtheria Toxin Receptor expression only in the PD-L2 expressing B cells, (3) 
CD-19 promotor driven expression of Cre recombinase protein. These mice 
provide an inducible knockout model where Diphtheria Toxin (DT) injection 
selectively deletes L2pB1 cells throughout the mouse. By providing injections of 
DT over the course of 4 days, we can successfully deplete upwards of 95% of 
L2pB1 cells from the mouse.[55] Depletion is confirmed through flow cytometry 
and subsequent analysis. 
Cell lines and 3D tumor spheroid formation 
B16F10 melanoma cells and MC38 colon adenocarcinoma cells were 
cultured on 10cm tissue culture plates (Corning), minimally passaged, and 
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maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% Heat Inactivated Fetal Bovine Serum (FBS), 2mM L-glutamine, 100mg/ml 
penicillin, and 100mg/ml streptomycin (all from Invitrogen-Gibco, Carlsbad, CA).  
B16F10 cells of passage number 4 or lower were grown on 10cm tissue 
culture plates to approximately 70%-90% confluence, maintaining log phase 
growth. Cells were washed with Phosphate Buffered Saline (PBS), no Ca+, no 
Mg+ (Invitrogen-Gibco, Carlsbad, CA). After washing with approximately 3mL of 
PBS, the cells are trypsinized with 2mL of trypsin (Invitrogen-Gibco, Carlsbad, 
CA) and incubated for 3 to 5 minutes at 37ºC. After incubation, add 8 to 10mL of 
supplemented DMEM to stop the trypsinization reaction. Briefly look at cells 
under a light microscope to check for detachment from plate bottom, if necessary 
tap the bottom of the plate to aid this detachment. Using a transfer pipet, transfer 
all media and cells from the plate to a 15mL tube and centrifuge the cells at 
1200rpm for 5 min to pellet the cells. Remove the supernatant, resuspend in 1mL 
of supplemented DMEM, and count the cells using a hemocytometer or 
automated cell counter. The B16F10 cells should now be in a single cell 
suspension and ready for use in spheroid formation. The same process for 
creating a single cell suspension is used for the MC38 cell line. 
The next step in the creation of the B16 spheroids is to make an 
appropriate amount of working spheroid formation media. Obtain 10X Spheroid 
Formation Matrix (SFM) (Trevigen, Gaithersburg, MD) and dilute to 1X in 
supplemented DMEM. The SFM remains liquid between 2 to 8ºC and is stored at 
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-80ºC, it is imperative to thaw on ice and use ice cold DMEM for these steps as 
above 8ºC the SFM begins to gel as the matrix takes shape. The final volume 
placed into each well is 50µL so, accounting for pipetting error, create enough 
final working volume to seed 10,000 B16F10 cells in 50µL of 1X SFM 
supplemented DMEM. Mix the B16F10 cells, the SFM, and the supplemented 
DMEM on ice to a planned volume at a concentration of 2x105 cells/mL. After this 
cell seeded working solution of DMEM and 1X SFM is created pipet 50µL of cell 
solution into each well of a 96 well, round bottom, ultra-low attachment (ULA) 
spheroid microplate. Be very careful while pipetting to avoid touching any sides 
or surfaces of the round bottom well. Once all desired wells are seeded, place 
ULA microplate in a centrifuge at 3200rpm for 5 minutes at 4ºC to bring cells to 
the center of round bottom wells and tightly pack them. Image cells under the 
light microscope once more to ensure central location and tight packing of the 
cells in the round bottom wells before placing in an incubator at 37ºC in 5%CO2. 
It is necessary to leave the spheroids undisturbed for two days to ensure a stable 
environment for unimpeded growth. After two days of undisturbed growth, 
carefully pipet 150µL of supplemented DMEM into each well. Pipet slowly and 
carefully to prevent movement from the central location in each round bottom 
well. From day two onward it is necessary to remove 100µL of media and refeed 
with 100µL of new supplemented DMEM media to ensure proper growth and 
longevity of the cells. The tumor spheroids should develop necrotic cores on day 
four from which point onward they are considered proper tumor spheroids as 
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opposed to loose cell aggregates. On day four we treated the spheroids with the 
immune cell treatment conditions described below. For this experiment, 24 wells 
were prepared each with a single tumor spheroid. There were three treatment 
conditions each using eight tumor spheroids for a sample size of n=8 per 
condition. 
The MC38 spheroids were instead created using the hanging drop method 
[49]. After creation of the single cell suspension of MC38 cells, the cells are 
concentrated to 2x105 cells/mL. The cell suspension drops are placed on the 
underside of the lid to a 10cm tissue culture plate. When the lid is inverted, the 
droplets, containing approximately 10,000 cells per 50µL droplet, are held in 
place by surface tension, as shown in Figure 4. Because of the microgravity 
environment and because cell-cell adhesion is the strongest attachment force 
imposed on the cells, the cells aggregate within each drop and then form 
spheroids at the free liquid-air interface. The tissue culture plate is kept in an 
incubator at 37ºC with 5% CO2 and left undisturbed for 4-6 days of unimpeded 
aggregation and spheroid formation. Additional care is taken to prevent the 
droplets from drying out, and the incubator is kept under constant observation to 
maintain the appropriate humidity to prevent evaporation of the liquid from the 
droplets. After the spheroids are formed, usually when they are visible to the 
naked eye, they are transferred from the droplet to a low adhesion plate, one 
spheroid per well of a 96 well plate, and resuspended in 100uL of supplemented 
DMEM. Two hours after transfer, the spheroids are treated with immune cells 
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and co-cultured for ten days as described below. This experiment utilized 60 
spheroids and five treatment conditions each using twelve MCTS for a sample 
size of n=12 per condition. The immune cell collection and treatment is described 
below. 
 
Figure 4: MC38 spheroid preparation through hanging drop method on 10cm tissue culture 
plate 
50uL drops containing 10,000 MC38 cells are placed on the lid of a 10cm tissue culture plate. 
Adhesion forces prevent the drop from falling after the lid is inverted and placed back onto the 
plate which contains 10mL of PBS or sterile DI H2O for hydration. The MC38 cells aggregate into 
spheroids in 4 to 6 days in this microgravity environment and aided by the lack of stronger cell-
plate adhesion forces. The spheroids are transferred from the lid of the plate to a well of an ultra-
low attachment 96 well microplate. 
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Mice preparation and peritoneal and spleen cell collection 
The present study utilized four male red mice between the ages of six to 
eight weeks. The mice are separated into two groups; two red mice were part of 
the DT injected and L2pB1 depleted group, while the other two mice were part of 
the pharmaceutical grade 0.9M normal saline (NS) (Invitrogen-Gibco Carlsbad, 
CA) injected group which would have a full syngeneic immune complement. The 
DT injected mice, referred to as the depleted group, were given intraperitoneal 
(i.p.) injections of DT in normal saline (List Biological Laboratories #150, 
Campbell, CA) at a concentration of 2µg/mL. The required dose to induce full 
depletion is 25ng of DT per gram of body weight. These injections were given 
once a day for a total of four days. The last day of injections is always completed 
the day before euthanasia and cell collection. The NS injected mice, referred to 
as the control group, are given similar volume injections simultaneously with the 
depleted group. NS injections are 12.5µL of NS per gram of body weight and are 
also done for four days with the last day falling prior to euthanasia and cell 
collection. All injections are done intraperitoneally under ABSL-2 standard 
precautions. 
On the day of euthanasia and cell collection, the mice are euthanized by 
CO2 inhalation with cervical dislocation as a secondary kill method. Immediately 
post-euthanasia the mice are dissected with the peritoneum left untouched to 
reveal the abdominal cavity. The peritoneal cavity washout is collected with 
Hank’s Buffered Salt Solution (HBSS) (Gibco-Invitrogen, Carlsbad, CA) 
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supplemented with 2%FBS (Sigma-Aldrich, St. Louis, MO). All work with cell 
suspensions is done on ice. Before dissection, one 10mL syringe and one 5mL 
syringe for each mouse is prepared by drawing 10 and 5mL of HBSS into the 
syringe. Using a 23 gauge ½ inch needle, the HBSS is injected into the 
abdominal cavity, following which the mouse is shaken to dislodge peritoneal 
immune cells, and the same syringe and needle are used to remove as much of 
the washout as possible. The collected HBSS and PCW are placed in 15mL 
tubes for further processing. 
After collection of the PCW, the mouse abdominal cavity is opened to 
remove the spleen. Whole spleens are collected and kept in R10 media; modified 
RPMI media (Gibco-Invitrogen, Carlsbad, CA) supplemented with 10%FBS 
(Sigma-Aldrich, St. Louis, MO), 2mM L-glutamine, 20mM HEPES buffer (Gibco-
Invitrogen, Carlsbad, CA), and 1% Penicillin and 1% Streptomycin (both from 
Corning, Corning, NY). The spleens are then ground and separated using a 
70um pore size cell strainer and kept in R10 media in a 50mL tube for further 
processing. 
After all euthanasia and cell collection, mice carcasses are collected and 
disposed of according to institutional safety protocols. 
Peritoneal cavity washout and splenocyte processing 
Once the immune cells have been collected, and mice have been 
disposed of as described above, and before treating our pre-formed 3D Tumor 
spheroids, we must process the PCW and spleen cells. First, immune cells are 
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centrifuged and pelleted at 1200rpm for 5 minutes following which all supernatant 
is removed. In the case of the spleen cells there will be an excess of erythrocytes 
so add 3 mL of red blood cell (RBC) lysis buffer (Qiagen, Hilden, Germany), 
resuspend the cell pellet and incubate for 5 minutes at 37ºC. If the peritoneal 
cavity wash cells have erythrocytes, add 3mL of RBC lysis buffer, resuspend, 
and incubate for 5 minutes at room temperature. After the RBC lysis buffer and 
cells have incubated for 5 minutes add 10 mL of ice-cold supplemented HBSS to 
stop the lysis reaction and centrifuge at 1200rpm for 5 minutes to pellet cells. 
Remove the supernatant and count cells; set aside 4 million PCW cells or 
splenocytes suspended in 4mL supplemented DMEM (concentration 1x106 
cells/mL) these will be for treatment conditions. The remaining cells (minimum 
2x106 PCW cells and similar or greater number of spleen cells ) should be 
centrifuged, decanted, and resuspended in FACS Buffer, PBS supplemented 
with 2% FBS, at a concentration of 20x106 cells/mL. These remaining cells are 
prepared for staining and flow cytometry. 
Tumor spheroid treatment with collected immune cells 
After four to six days of spheroid growth, the necrotic cores have formed, 
and the tumor spheroids are ready to treat with immune cells. One group of 
spheroids is used as a negative control group (n=8), where DMEM media is 
refreshed every two to three days. The remaining groups will be treated with 
various immune cells at a target: effector ratio of 1:10, (tumor cell number 
seeded on day 1: immune cell number added on day 7). In the B16F10 spheroid 
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experiment, our three conditions each with n=8 are non-treated (negative 
control), wild-type/syngeneic PCW treated, and L2pB1 cell depleted PCW 
treated. In the MC38 spheroid experiment, the five treatment conditions are non-
treated (negative control), wild-type/syngeneic PCW treated, L2pB1 cell depleted 
PCW treated, wild-type/syngeneic splenocyte treated, and L2pB1 cell depleted 
splenocyte treated. An additional study of the MC38 spheroids also included a 
split of each of these five conditions into LPS co-stimulated or unstimulated 
conditions to better mimic the in vivo environment with co-stimulation from other 
immune cells or present pathogens. Stimulated conditions were kept in media 
that had 1ug/mL of Lipopolysaccharide (LPS) from E. coli. All spheroids were 
seeded with 10,000 cells, so all spheroids were treated with 100,000 immune 
cells. After treatment, the treated spheroids microplate is placed back into 
incubation at 37ºC at 5% CO2 until ready for image cytometry. 
Flow cytometry 
The cells prepared for flow cytometry had been previously pelleted and 
resuspended to a concentration of 2x107 cells/mL in FACS buffer. First, stain all 
samples and the live/dead control with Zombie AquaTM (BioLegend, CA), an 
amine-reactive fluorescent dye that is non-permeant to live cells and only 
permeant to cells with compromised membranes, for 20 minutes on ice. After 
staining with Zombie AquaTM, these cell samples should be washed and then 
incubated with Fc Block (anti-CD32/anti CD-16 mAb) (BioLegend, CA) for 15 
minutes on ice. The remaining stains utilized for flow cytometric analysis of the 
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peritoneal and splenic lymphocytes are included in Table 2. A master mix of 2X 
dilution is created utilizing all of these stains. After staining with the Fc Block mix, 
add the Antibody Master Mix to each sample and mix well. After addition of the 
final staining mixture, cells should be incubated for 45 minutes on ice. Following 
the incubation period, the flow cytometry samples should be washed three times. 
After the final wash cycle, the cells are resuspended in 300uL of FACS buffer, 
transferred to FACS tubes, wrapped in aluminum foil to prevent light degradation 
of the fluorophores, and taken to the BD LSRII for flow cytometry. Compensation 
controls are prepared using a single antibody stain on one drop of compensation 
beads processed in the same way as the cell samples but without Fc Block. TdT 
expressing B16F10 cells or other cell lines can be used as a compensation 
control for TdT expression inherent to the L2pB1 cells of the red mice. A half and 
half mixture of heat-killed splenocytes and live splenocytes with added Zombie 
AquaTM stain can be used as a Live/Dead compensation for Zombie AquaTM. 
Lastly, an unstained group of splenocytes (approx. 2x106 cells) suspended in 
300uL, can serve as size and granularity controls for the lymphocytes. 
After completion of the staining protocol Flow cytometric data is collected 
with BD LSRII and analyzed using FlowJo software (TreeStar, OR). Standard 
protocols for operation and analysis are used, and FlowJo analysis and gating 
strategy is presented in results. 
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Refeeding and maintenance  
The spheroids should be refed every two to three. The spheroids are kept 
with a working volume of 200µL of supplemented DMEM media. On every other 
day, usually before imaging, the spheroids are refed with fresh media. If the 
spheroids are accidentally moved from the center of the wells they can be 
pushed back into proper position in the round bottom well using gentle 
centrifugation of 500g for approximately 3 minutes. 
Calcein-AM and PI cytotoxicity assay staining 
Cytotoxicity assays provide an in vitro evaluation of lytic and apoptotic 
activity of immune cells against tumors or target cells. Calcein acetoxymethyl 
(AM) has good retention in targets, low pH sensitivity, and is frequently used to 
stain viable cells. Inside cells, it is converted by intracellular esterase into a polar 
lipid insoluble fluorescent product (Calcein) that is retained in cells with intact 
membranes and released by a damaged membrane or dead cells producing a 
bright green signal.[56] Propidium Iodide (PI) is a fluorogenic nuclear compound 
that binds to nucleic acids in apoptotic or dead cells that display a broad 
fluorescence peak in the red fluorescence channels.[57] In this way using a 
Calcein-AM/PI dual stain we can visualize the necrotic core and live cell content 
in tumor spheroids via this apoptosis and cytotoxicity assay. 
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Table 2: Staining Panel for Cell Samples. 
Cell samples are stained using a panel combining the following antibody stains mixed at the indicated dilutions and amounts into FACS 
buffer. The staining buffer created using this table is a 2x dilution meant to be added to an equal volume of Fc Block solution after the Fc 
Block incubation period has completed. The listed volume of each antibody is added per drop of compensation beads used for flow 
cytometry compensation controls. 
Staining Reagent 
Excitation 
Max/ 
Emission Max 
(nm) 
From 
Final Dilution 
for cells 
Dilution for 
MM 
Volume per 
drop of 
compensation 
beads (µL) 
Volume per 
50µL of MM 
(µL) 
B220 PerCP-Cy5.5 482nm/676nm 
BD 
Biosciences 
Pharmingen 
1:200 1:100 0.5 0.5 
CD5 PE-Cy7 
496nm/785nm 
BD 
Biosciences 
Pharmingen 
1:200 1:100 0.1 0.5 
CD19 BUV395 348nm/395nm 
BD 
Biosciences 
Pharmingen 
1:100 1:50 0.5 1 
PD-L2 BV421 407nm/421nm 
BD 
Biosciences 
Pharmingen 
1:50 1:25 0.1 2 
IgM APC 650nm/660nm BioLegend 1:400 1:200 0.1 0.25 
Mac1/CD11b APC-Cy7 650nm/785nm 
BD 
Biosciences 
Pharmingen 
1:1000 1:500 0.2 0.1 
 
 56 
Calcein-AM (Nexcelom Bioscience, Lawrence, MA #CS1-0119) is stored 
at -80ºC and should be brought to room temperature before adding into wells. PI 
is stored at 4ºC and should also be brought to room temperature before adding to 
spheroid wells. The working solution should be a 2000x dilution of the Calcein 
AM stock and have a 2ug/mL concentration of PI. Spheroids are incubated with 
the staining solution for 45 minutes to one hour at 37ºC and 5% CO2. 
After this time has passed the spheroids are ready for their final imaging 
and image cytometry. This staining will disrupt the spheroids and lymphocytes 
and is used as part of the endpoint of the experiment to visualize the progression 
of the necrotic core and possible lymphocyte infiltration into the tumor spheroid. 
Image cytometry 
For the B16F10 spheroid experiment, we utilized the Nexcelom Celigo 
Image Cytometer. For the MC38 spheroid experiment, we utilized a KEYENCE 
BZ-X710 fluorescence microscope and the associated analysis programs. 
Beginning on the day of treatment and proceeding every day or every two 
days until day 20 (B16F10) or Day 10(MC38) after treatment, spheroids are 
imaged, and growth or inhibition is analyzed by measuring spheroid cross-
sectional area or volume. 
The Celigo utilizes a transmission, and epifluorescence optical setup for 
one bright-field and four fluorescence channels (Blue, Green, Red, Far-Red) with 
high power LED to perform plate based image cytometric analysis. The imaging 
optics can capture uniform images of all 96 wells on a standard microplate. 
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Celigo can also perform auto-focusing in the well, based on image contrast or 
bottom surface thickness. 
The KEYENCE BZ-X710 has the similar high throughput capability and 
offers the Z-stack image acquisition and full focus functions that allow us to take 
multiple images at pre-set intervals along the Z-axis of the spheroid within each 
well. The Z-stack functionality allows much more accurate analyses of spheroid 
size and measurements of growth or inhibition. 
All spheroids are imaged under the same settings and using the same 
lenses and fluorescent filters within each experiment. After image acquisition, the 
images are analyzed using the Nexcelom Celigo software or the KEYENCE 
analysis software and data is recorded for later analysis in Matlab or MS Excel. 
Figure 5 on the following page presents a schematic taken from Vinci et al., 
“Advances in establishment and analysis of three-dimensional tumor spheroid 
based function assays for target validation and drug evaluation” that represents 
the methods we utilized in the spheroid analysis [58]. 
IgM ELISA 
In addition to identifying an inhibitory effect carried out by L2pB1 effector 
cells, we sought to understand the mechanism behind this B1a cell mediated 
toxic effect. To do this, we completed an ELISA testing for the presence of total 
IgM in stimulated and unstimulated PCW and splenocyte populations that were 
full or depleted of L2pB1 cells. The cell groups tested were L2pB1 cell depleted 
PCW, L2pB1 cell depleted splenocytes, full syngeneic PCW, and full syngeneic 
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splenocytes. The cells were kept in RPMI 1640 media supplemented with 10% 
FBS, and the stimulated groups were stimulated with 1ug/mL Lipopolysaccharide 
(LPS). Cells were maintained in 12 well plates at a concentration of 4x106 
cells/mL and incubated at 37ºC and 5%CO2 for 48 hours. After 48 hours the 
supernatant is collected from each well and processed to ensure lack of cell 
debris. The supernatant is stored at -20ºC until the time of use and is only stable 
for one freeze-thaw cycle. The supernatant is diluted and analyzed via a total 
mouse IgM sandwich ELISA. The primary antibody used was for total mouse 
Ig(H+L), and the secondary antibody was pan-mouse IgM specific and 
conjugated to Horse Radish Peroxidase (HRP). The plate was read on a BMG 
LABTECH POLARstar Optima plate reader. The analysis was completed in MS 
Excel. 
Statistical analysis 
Comparisons between the spheroid treatment groups — the untreated 
group, the L2pB1 depleted group, the full syngeneic PCW group, and the 
splenocyte groups where applicable — was accomplished using student’s t-tests 
between samples following outlier exclusion using an Interquartile Range test on 
standard non-normalized data. The student’s t-tests were done on the endpoints 
to determine the overall effect of the immune response in diverting growth from 
the non-treated control. All analysis was completed in MATLAB or MS Excel. P-
values <0.05 were considered significant. 
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Figure 5: Vinci et al.’s High throughput standardized method for generation, imaging, and 
analysis of tumor spheroids. 
(a) Spheroids are generated and maintained in round bottom, 96-well ULA plates. Vinci et al. ’s 
method involved only the low adhesion surface and centrifugation method, while we also included 
spheroid generation by hanging drop method. (b) Automated imaging and analysis carried out. 
Vinci et al.‘s method used only the Celigo and the Colony Counting Embryoid Body application 
with a 1/16 field of view. Our method for the Celigo image cytometer and the B16F10 spheroids 
utilized the Tumorsphere application and a full-well field of view at 4x magnification. Our method 
for the MC38 spheroids and the KEYENCE BZ-X710 involved capturing Z-stack images of the 
spheroids at 10X magnification and utilizing the analysis program’s Hybrid Cell Counter 
application to measure spheroid area and major/minor axis to estimate spheroid volume [58]. 
  
 60 
RESULTS 
L2pB1 cell depletion 
Using the established method of four consecutive intraperitoneal 
Diphtheria Toxin injections, it is possible to achieve greater than 95% depletion of 
L2pB1 cells in the peritoneal cavity in the treated mouse. Although this depletion 
is an established routine procedure, many factors might affect the depletion 
efficiency, therefore it is necessary to confirm this depletion for each mouse 
before initiation of the co-culture assay. The depletion of L2pB1 cells is confirmed 
by Flow Cytometry analysis using the gating strategy shown in Figure 6. The 
gating strategy first goes eliminates doublets by selecting only single cells, after 
which only live cells are chosen for further analysis. B cells are chosen based on 
expression of pan-B cell marker CD19 and immune cell marker B220. After 
selecting this population, we gate on CD19 and IgM double positive cells which is 
the B1 cell population. From the B1 cell population, we gate on IgM and CD5 
high expressing cells which helps Identify B1a cell. The final display is the B1a 
cell population shown on a TdTomato and PD-L2 graph. This final graph is 
compared among mice and from this we determine the L2pB1 cell population and 
depletion percentage in DT treated mice. 
The depletion achieved is demonstrated in Figure 7. These results are 
from two of the mice used in further experimentation, and the results are 
representative of the general depletion achieved under normal conditions and 
with successful injections. The flow cytometry results reveal three critical 
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findings. First is that the depletion of L2pB1 cells in the peritoneal immune cells 
achieved by four consecutive DT injections is higher than 95% depletion. 
Second, when comparing PCW and splenocyte immune cell collections, we see 
that the splenocytes have a much smaller percentage of B1 cells and as a result, 
they have a much smaller population of L2pB1 cells than the population that is 
found in the peritoneum. Finally, we see that although there is a smaller L2pB1 
cell population found in the wild-type spleen, the DT injected mouse spleen still 
demonstrates a significant depletion of L2pB1 cells. Table 3 reiterates this 
depletion by listing the immune cell population sizes as a percentage of live cells 
analyzed. 
Table 3: Numeric Analysis of L2pB1 cell depletion 
Taken from the same representative mice shown in Figure 7, this data shows that regardless of 
total number of live cells analyzed the  resulting depletion of L2pB1 cells reaches over 95% 
reduction in the population of L2pB1 cells while also demonstrating a negligible effect on the size 
of the L2nB1 cell population or other immune cell populations within the mouse. 
Sample 
Live Cells 
(Total 
Number) B cells* B1 cells* B1a cells* 
L2pB1 
Cells* 
L2nB1 
cells* 
Control Mouse 
PCW 448000 64.30% 26.00% 10.80% 3.960% 6.340% 
L2pB1 Depleted 
Mouse -PCW 428000 63.30% 26.00% 8.57% 0.050% 8.280% 
Control Mouse - 
Splenocytes 594000 60.30% 2.13% 0.30% 0.024% 0.260% 
L2pB1 Depleted 
Mouse - 
Splenocytes 649000 57.00% 2.53% 0.34% 0.002% 0.330% 
*Reported as a percent of Live Cells 
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Figure 6: Gating strategy to identify the population of L2pB1 cells in a given immune cell 
collection 
Initially we gate on all cells. Following which we do two rounds of singlet extraction. After singlet 
extraction, we select only live cells for further analysis. From the population of live cells, we gate 
on total B cell populations, B220 high/mid and CD19 high cells. From the total B cell population 
we gate on the population of B1 cells, CD19 high and IgM high. From B1 cells we then gate on 
CD5 high expression cells which are the B1a cell population. Finally, from the B1a cell population, 
we determine the percent of the L2pB1 cell population and when compared between wild-type 
and DT injected mice we determine the percentage depletion. 
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Figure 7: L2pB1 cell depletion 
(a) We see that from similar starting populations of collected peritoneal immune cells the 
Diphtheria Toxin treated mice have an almost complete depletion of L2pB1 cells. (b) Also, in the 
splenocyte collections, although there are altogether fewer B1 cells, we still see a reduction in the 
total number of L2pB1 cells present. Together this data demonstrates that although the DT 
treated mice are injected intraperitoneally, the depletion of L2pB1 cells is systemic, and the DT 
diffuses well into the mouse periphery. 
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Loss of tumor inhibition function in L2pB1 cell depleted immune 
treatments demonstrated on B16F10 Spheroids 
B16F10 spheroids were cultured using the centrifugation compaction and 
ultra-low attachment (ULA) method. Upon establishment of a necrotic core these 
spheroids were treated with full syngeneic peritoneal cavity immune cells (control 
PCW), or L2pB1 cell depleted peritoneal cavity cells (DT PCW), and the growth 
of these treatment group spheroids was compared to the untreated group of 
spheroids (Non-Treated) which were maintained in standard media for the 
duration for the treatment. 
 
Figure 8: Time course of B16F10 spheroid growth inhibition 
Qualitatively we see that in the presence of L2pB1 cells the syngeneic (control) PCW treatment 
has a significant effect in the growth inhibition of 3D tumor spheroids. Conversely, the L2pB1 cell 
depleted treatment (DT PCW) has a diminished inhibitory effect. In comparison to the uninhibited 
growth of the Non-Treated condition, the control PCW treatment has a significantly smaller 
average cross-sectional area. 
Analysis of cross-sectional area (CSA) and interquartile range outlier 
exclusion was performed in MATLAB. A representative spheroid from each 
treatment group was chosen based on proximity to median size and images 
plotting the time course of growth for these spheroids are shown in Figure 8. The 
non-uniform growth of B16F10 spheroids was an issue and therefore the 
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displayed time course in Figure 8 does not visually reflect the inhibitory effect 
provided by the full syngeneic peritoneal immune cell treatment.  
The graph displaying the mean cross-sectional area of the spheroids, 
normalized to the average size at the start of treatment, over the course of 
treatment displayed in Figure 9 provides a more quantitative representation 
showing the tumor inhibitory effect of the syngeneic peritoneal immune cell 
treatment. This quantitative analysis demonstrated a significant decrease in 
tumor size following treatment with control PCW but no significant reduction in 
growth following treatment with DT PCW. 
Figure 9: Quantitative analysis of B16F10 spheroid growth measured by CSA 
The growth of each treatment condition (n-8 per condition) as measured via image cytometry 
using the cross-sectional area (CSA) shows inhibited growth when spheroids are treated with 
syngeneic (control) PCW cells in comparison to the Non-Treated condition (p<0.01). Depletion of 
L2pB1 cells diminishes the anti-tumor effects, and these spheroids show a negligible difference 
from the untreated control group. 
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The only differentiator between the control PCW and DT PCW treatments 
is the presence of L2pB1 cells. There is a significant difference between the 
spheroid size of these treatments and between the control PCW and the Non-
Treated condition (P<0.01) indicating a robust anti-tumor effect mediated in some 
way by the L2pB1 cells. 
Growth inhibition of MC38 spheroids adds confirmation to the B16 
spheroid findings. 
MC38 spheroids were established using the hanging drop method of 
spheroid formation, were co-cultured on ULA plates, and were imaged and 
analyzed using the KEYENCE BZ-X710 fluorescent microscope and analysis 
software. Upon establishment of the necrotic core and the following transfer from 
hanging drops to the ULA microplate these spheroids were treated with control 
PCW, L2pB1 cell depleted PCW, control splenocytes, L2pB1 cell depleted 
splenocytes and a Non-Treated control condition. All conditions also were divided 
into a Lipopolysaccharide (LPS) co-stimulated and non-stimulated condition for a 
total of 10 conditions all with a sample size (n=6). Collective analysis of growth 
rates and outlier exclusion was completed in MS Excel. Data collected from each 
tumor spheroid included cross-sectional area and major and minor axis length. 
Using this data we were able to generate a volumetric estimation using a 
simplified ellipsoid formula utilizing the obtained cross-sectional area and the 
minor axis data. Estimations were made keeping the inherent biology of the 
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tumor cells and model environment in mind and are believed to be accurate 
within 95% of the actual tumor sphere volume [59], [60]. 
A representative spheroid from each treatment condition is shown in 
Figure 10. Figure 10 demonstrates the time course of the treatments for each 
condition beginning at the start of treatment and continuing until day 10 when the 
spheroids were stained with Calcein AM/PI to obtain information on the size of 
the necrotic core and live, actively dividing or quiescent cell rim. These results 
demonstrate a similarly robust antitumor effect of the control PCW treatment as 
well as demonstrating the enhancement of this anti-tumor effect that results from 
co-stimulation with LPS, a known stimulator of L2pB1 cell activity. The L2pB1 cell 
depleted PCW treatments (DT PCW) show some level of tumor inhibition but do 
not come close to the same efficacy as in the full syngeneic control treatments, a 
result that is mirrored in the LPS stimulated DT PCW treatments. Neither 
splenocyte treatment regardless of LPS co-stimulation resulted in any deviation 
of tumor growth from the Non-Treated condition. 
Analysis of the non-stimulated treatments carried out in MS Excel 
revealed a significant difference in tumor spheroid volume resulting from the full 
syngeneic control PCW treatments when taken in comparison with the Non-
Treated condition (P<0.001). The spheroid volume resulting from control PCW 
treatment was also significantly smaller than the tumor size of the DT PCW 
treatments (P<0.05). There was no significant difference in mean spheroid 
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volume between splenocyte treatment and the non-treated condition. These 
results are demonstrated graphically in Figure 11(a).  
 
Figure 10: Time course of MC38 spheroid inhibition, unstimulated and with LPS co-
stimulation. 
(a) The MC38 spheroids were treated with the various naïve or unstimulated immune cell 
treatments for ten days. Conditions were: NT=Non-Treated, CP=Control PCW, DP=DT or L2pB1 
Depleted PCW, CS=Control Splenocytes and DS=DT or L2pB1 Depleted Splenocytes. In this 
figure, we see a robust inhibition of tumor growth by the control PCW condition when compared 
to the Non-Treated condition, and a much less substantial inhibition by the L2pB1 cell Depleted 
PCW. Both Splenocyte treatments result in growth rates indistinguishable from the Non-Treated 
condition. (b) The conditions included in a.) are also carried out with the inclusion of LPS co-
stimulation, denoted by the “L”. In these treatments, we see an even more pronounced tumor 
inhibition from the control PCW when compared to the Non-treated condition. Spheroids from all 
other treatment conditions do not significantly deviate in size from the unstimulated groups. 
A similar analysis of the LPS co-stimulated treatment conditions revealed 
an even more robust inhibition of tumor spheroid growth. The mean volume of 
LPS co-stimulated Control PCW treated spheroids was much smaller than the 
mean volume of the LPS co-stimulated Non-Treated Spheroids (P<0.0001). The 
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enhancement of antitumor effect through LPS co-stimulation mediated by the 
L2pB1 cells is more visible in these spheroids as there is again a significant 
reduction in the mean volume of the control PCW spheroids when compared to 
the co-stimulated DT PCW treated spheroids (P<0.001). Again we see no 
difference in spheroid size between the splenocyte conditions or the Non-treated 
condition. The quantitative analysis of the LPS co-stimulated growth inhibition is 
demonstrated in Figure 11(b). 
L2pB1 cell IgM production 
In order to work towards understanding the mechanism driving the L2pB1 
cell mediated anti-tumor effect, we collected control (wild-type) PCW and L2pB1 
cell depleted (DT) PCW for analysis of stimulated and constitutive IgM 
production. Control and DT PCW were concentrated to approximately 4 million 
cells per milliliter of RPMI medium. The two conditions were then either 
stimulated with 1ug/mL LPS or left unstimulated for the duration of the incubation 
period. The cells were then allowed to incubate for 48 hours after which the 
supernatant was collected, processed and analyzed for IgM concentration with a 
fast, sandwich ELISA. The analysis was completed in MS Excel, and the results 
of this ELISA are shown in Figure 12. In Figure 12, we see that the Control PCW 
greatly out-produces the L2pB1 cell depleted in both the unstimulated and LPS 
stimulated conditions (P<0.0001). 
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Figure 11: Quantitative analysis of MC38 spheroid growth measured by Volume estimate 
(a) The growth of each non-stimulated treatment condition (n=6 per condition) as measured via 
volumetric estimate derived from the image cytometry measurement of CSA and minor axis 
measurement. These results show significant inhibition of growth of MC38 spheroids when 
treated with syngeneic (control) PCW cells in comparison to the Non-Treated condition 
(P<0.0001) and to the DT PCW condition (P<0.05). Depletion of L2pB1 cells diminishes the anti-
tumor effects, and the DT PCW treated spheroids show a reduced inhibition of tumor growth. 
Neither Splenocyte treatment causes a significant divergence in spheroid growth when compared 
to the Non-Treated control. (b) The results generated in the non-stimulated treatments are further 
compounded in the LPS stimulated conditions. L2pB1 cells in the Control PCW are further 
stimulated by LPS, and this enhances their anti-tumor response resulting in a more robust 
reduction in tumor size when compared to the Non-Treated + LPS condition (P<0.0001) and the 
DT PCW + LPS condition (P<0.001). 
(a) 
(b) 
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Figure 12: IgM concentration in the supernatant of stimulated or unstimulated PCW 
collections. 
L2pB1 cells had been known to be potent constitutive secretors of IgM, so it is not surprising to 
see that depletion of these cells dramatically reduces the amount of IgM constitutively produced 
by the PCW immune cell collections. However, it is interesting to see that following LPS 
stimulation, the L2pB1 cell depleted (DT) PCW still exhibits no increase in IgM production. There 
was expected to be an increase in IgM production for any LPS sensitive B cells regardless of the 
presence of L2pB1 cells, but the ELISA carried out here shows that the depletion of L2pB1 cells 
considerably diminishes the sensitivity of the immune cell collection to LPS stimulation. In the 
control PCW, we see an approximate doubling in IgM production when compared to constitutive 
IgM secretion within the same group. 
The L2pB1 cells were previously known to be potent constitutive secretors 
of natural IgM (nIgM), but here we see that when stimulated with LPS, the L2pB1 
cells play a huge role in increasing overall production of IgM by the entire 
immune cell collection.  
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DISCUSSION 
The role of B cells in the immune response to cancer and in generating 
immunotherapeutics for the treatment of neoplasms has primarily focused on the 
utilization of monoclonal IgG antibodies to block immunosurveillance evasion 
markers on tumor cells [61], [62]. Studies into the role of B cells in the anti-tumor 
response have also focused primarily on the regulatory B cell response that is 
present in dysregulated immune system responses to certain tumors and as a 
result of B-cell malignancies [63]–[66]. Currently, the role of the B cell in the anti-
tumor response is poorly understood. However, information regarding B-cell 
subsets and the broad and varied role that B-cells and B-cell secreted products 
such as immunoglobulins (Ig), and stimulatory cytokines can have in directing 
and enhancing the immune response of other cells has triggered a level of 
interest in understanding the precise role of B-cell mediated anti-tumor immunity 
[64], [67]. This interest in developing further understanding of the B-cell role in 
cancer immunology has led to this analysis of the L2pB1 cell subset of B 
lymphocyte response to cancer in an in vitro 3D tumor spheroid model. 
Flow cytometry analysis of the Diphtheria toxin mediated, L2pB1 cell 
depletion in a genetically engineered mouse model. 
Analyses of immune cell collections taken from the wild-type mouse 
confirm previous studies and understanding of the general B cell subset make-up 
of the naïve murine immune system. In the Peritoneum, B cells make up the 
majority of live cells, and of this population, B1a cells are the most significant 
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subset. In comparison, the spleen B cell population has a much smaller B1 cell 
subset as this is the location for B2 cell maintenance and maturation and the B1 
cells found in the spleen tend to be CD5 negative B-1 cells indicating they are 
either B1b cells or B1a cells that lost CD5 expression upon exiting the peritoneal 
cavity. 
From this understanding gained from literature and analysis of the wild-
type mice, we see that regardless of initial population size, the DT injections is 
selected mice are working as intended and providing a >95% depletion in the 
overall population of L2pB1 cells. Additionally, while there is significant depletion 
of L2pB1 cells, we see no significant change in the population size of any other B 
cell, or another immune cell, subset. We also see that the depletion of L2pB1 
cells extends to the splenocyte population which demonstrates that the 
intraperitoneal injections diffuse into the mouse periphery and deplete L2pB1 
cells throughout the body. Thus, the DT treated mice are excellent models for the 
study of L2pB1 cell specific activity when used for comparison against wild-type 
mice. 
L2pB1 cell mediated inhibition of 3D B16F10 spheroid growth 
B16F10 cells are very robust cancer cells that have an inferior self-antigen 
presentation due to low levels of constitutive expression of MHC class I 
molecules when cultured in vitro [68]. The noticeable reduction in growth rate of 
the B16F10 spheroid when co-cultured in the presence of immune cell collections 
 74 
containing regular numbers of L2pB1 cells is, therefore, a positive indication 
towards the overall anti-tumor role of L2pB1 cells in the innate immune response. 
The issue with B16F10 spheroid uniformity was an effect of the methods 
used to culture these spheroids. The use of centrifugation compaction and non-
adhesive microplates is simple to perform and easy to scale up but can lead to 
spheroid to spheroid differences in cell number, size, and shape. The non-
spherical 3D shape of the B16F10 spheroids, therefore, did not lend them to the 
accurate volumetric estimation of spheroid size. However, we find that the use of 
Cross Sectional Area (CSA) of the largest cross section is of these spheroids is 
an accurate measure of overall spheroid size and a reliable indicator of growth 
rate or growth inhibition. Additionally, differences in starting spheroid size were 
overcome by normalization to the size at the start of treatment. 
The growth inhibition achieved by syngeneic PCW but not by L2pB1 cell 
depleted PCW was previously established in 2D monolayer cultures (unpublished 
data from Zhong Lab). The reproduction of the growth inhibition achieved by 
syngeneic PCW and not by L2pB1 cell depleted PCW in a 3D model is, 
therefore, a powerful confirmation of these earlier studies in a better in vitro 
model of tumor growth. 
L2pB1 cell mediated inhibition of 3D MC38 spheroid growth 
MC38 cells are stronger constitutive antigen presenters than B16F10 cells 
and are therefore slightly more susceptible to cell-mediated cytotoxicity in co-
culture assay. However, studies of cytotoxicity have recently focused solely on 
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the effect of CD8+ T-cells and NK cells. The use of MC38 spheroids in co-culture 
studies of B-cell mediated cytotoxicity is, therefore, an exciting avenue for study. 
The results of ten-day co-culture of the MC38 spheroids with stimulated or 
unstimulated immune cell collection demonstrate two profound findings. First, we 
confirm the robust anti-tumor activity of B1a cells and specifically of L2pB1 cells. 
We see a significant inhibition of tumor growth in the syngeneic peritoneal 
immune cell treatments. The second greatest inhibition in spheroid growth comes 
from the L2pB1 cell peritoneal immune cell treatment which is likely because 
although the L2pB1 cell activity is removed, there is still a reasonably large 
macrophage and L2nB1 cell presence. Both Macrophages and L2nB1 cells may 
have some effects in general non-specific inhibition of cancer cell growth, but 
lack the targeted, robust inhibition conferred by the L2pB1 cell population. The 
negligible size of the L2pB1 cell population in the spleen, regardless of depletion 
treatment, and the resulting lack of any anti-tumor effect in either of the 
splenocyte treatments, simulated or otherwise, is yet another reliable indicator of 
the essential role of L2pB1 cells in mediating the anti-tumor response. 
The second finding of particular interest is the enhancement of tumor 
inhibition in the LPS stimulated full syngeneic treatment when compared to the 
unstimulated full syngeneic treatment. L2pB1 cells have previously been shown 
to respond to LPS stimulation, but the resulting reduction in tumor size was 
nonetheless a significant outcome that points towards the crucial role of cell-cell 
interaction and co-stimulation in the total immune response. The stimulation of 
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L2pB1 cells with LPS likely resulted in further, downstream increases in immune 
cell proliferation and enhancement of the complete immune response to the 
tumor cells. The results of the IgM ELISA further strengthen this theory of 
downstream L2pB1 cell mediated immune cell activation. 
Due to use of the hanging drop method of spheroid formation, the MC38 
spheroids were much rounder and closer in size. Therefore interquartile outlier 
exclusion was unnecessary and did not reject any of the experimental spheroids. 
Also, the spherical nature of these 3D cultures led to accurate volume 
estimations of spheroid size. The mean spheroid size at the start of treatment 
was similar enough for each treatment condition that normalization was not 
necessary and the resulting raw data demonstrated the potent inhibitory effect of 
the L2pB1 cell PCW treatment. 
IgM ELISA 
Perhaps the most surprising finding of this study is the surprising loss of 
stimulated IgM production resulting from depletion of L2pB1 cells in peritoneal 
immune cells collections. L2pB1 cells are strong constitutive secretors of IgM, 
they are the source of the early antigen-independent IgM secretion, and loss of 
these cells is expected to cause a reduction in the unstimulated production of 
IgM. However, the reduction of stimulated IgM production in L2pB1 cell depleted 
PCW even after LPS stimulation is worthy of further investigation. The reduction 
of stimulated IgM production is likely achieved through co-stimulation through 
suspected cell-cell interactions or other activating or stimulatory cytokines 
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released in by stimulated L2pB1 cells that cause other B cells to respond by 
increasing IgM production. Without L2pB1 cells to initiate the LPS response, IgM 
production does not increase from the already reduced constitutive levels of 
production. 
The results of the IgM ELISA on the supernatant of stimulated and 
unstimulated Control and DT PCW indicate a possible IgM mediated mechanism 
behind the L2pB1 cell tumor inhibition. Previous studies have shown that L2pB1 
cells produce IgM that is oligo-specific for dsDNA, PtC, and other non-peptide 
related epitopes that are likely to be exposed in the rapidly changing and high 
cellular activity environment of growing, small, avascular tumors. The possible 
binding of L2pB1 cell produced IgM to specific cancer cell epitopes merits further 
investigation. 
Implications for Future Research 
Past studies have shown that L2pB1 cells have a biased immunoglobulin 
repertoire that is enriched for self-reactivity as compared with outer B1 cell 
subsets. Also, L2pB1 cells present antigen more potently and undergo isotype 
switching more readily under cytokine stimulation [5]. While these characteristics 
may suggest that L2pB1 cells play a pathophysiological role in autoimmune 
dyscrasia, there is also reason to believe in an anti-tumor role of the L2pB1 cell 
based on recent studies involving the need of natural IgM and B1a cells in 
immune surveillance and early identification of transformed (malignant) cells 
[2][3]. In this study, we attempted to identify the role of L2pB1 cells in the 
 78 
antitumor immune response. We demonstrated that L2pB1 cells are essential for 
the inhibition of 3D tumor spheroids by syngeneic peritoneal immune cells. The 
major findings of this study include demonstrating the effect of L2pB1 cells in 
tumor inhibition both qualitatively through light microscopy and cellular 
cytotoxicity staining and quantitatively through image cytometry. We have shown 
that there is significant inhibition of tumor growth over the course of 10 to 16 days 
when established tumor spheroids are treated with syngeneic peritoneal immune 
cells. Furthermore, we showed the reversion of tumor inhibition following the 
depletion of L2pB1 cells in our inducible knockout model and how the absence of 
just this one significant B cell subset allows tumor growth to proceed as though it 
is untreated. We also demonstrated the use of 3D spheroids using two distinct 
cancer cell lines, B16F10 melanoma and MC38 colon adenocarcinoma, to 
provide a robust and high throughput model for immune cell invasion and 
response in an avascular tumor microenvironment. Lastly, we completed 
preliminary work in the analysis of L2pB1 cell secreted IgM that may indicate a 
possible mechanism behind the specific anti-tumor response of L2pB1 cells. 
Further studies will involve identifying which B cell receptors and secreted 
immunoglobulins of the L2pB1 cell are directly engaged and possibly responsible 
for the robust tumor response seen here. Additionally, fluorescent labeled 
immune and cancer cells can be utilized in time-lapse studies of 3D spheroid co-
cultures. These time-lapse studies can demonstrate the L2pB1 cell infiltration of 
tumor spheroids and the phagocytosis or lipoptosis of tumor cells by the 
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activated L2pB1 cells. Already underway are immunohistochemistry studies on 
the binding patterns of specific L2pB1 cell monoclonal antibodies on various 
cancer and non-transformed tissue to identify what antigens or epitopes on the 
cancer cell surface or microenvironment the fo which the L2pB1 cell IgM has a 
specific affinity. Lastly, the robust anti-tumor effect of L2pB1 cells demonstrated 
in 3D cell cultures give a strong positive indication that similar effects would be 
reproducible in vivo, and these studies are also underway or nearing completion. 
Our results suggested that immune cells from the peritoneal cavity but not 
spleen have anti-tumor functions. In particular, peritoneal L2pB1 cells play an 
essential role in cancer inhibition. Future studies of L2pB1 cells and their anti-
tumor functions could result in novel immunotherapy of cancer.[69] 
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